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Abstract
Targeted radionuclide therapy (TRT) is an effective treatment for metastatic prostate cancer.
This thesis develops a convolution-based dosimetric method for TRT and validates its
performance against a Monte Carlo (MC) simulation method, egs_mird, developed in our
laboratory.
The research completed includes: 1) validating egs_mird by generating dose point kernels
(DPKs) for

90

Y,

131

I and

177

Lu and comparing them with MCNP4C, PENELOPE and

GEANT4 DPK in literature, and 2) comparing TRT dosimetry of prostate cancer patients
obtained using the convolution method and egs_mird.
egs_mird DPKs for

90

Y and

131

I agreed with those from other MC codes. The discrepancy

between 177Lu DPK and literature was due to differences in emission spectra used in the MC
simulation. The mean doses in the prostate and critical organs as evaluated by the
convolution method were 5-7% lower than egs_mird due to density inhomogeneities.
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Lay Abstract
Prostate cancer (PCa) is the most commonly diagnosed cancer in men and the second leading
cause of cancer-related deaths in Canada. Besides standard treatment methods such as
surgery, hormone therapy, and chemotherapy, targeted radionuclide therapy (TRT) is a newer
effective method to treat PCa that has spread to other parts of the body. TRT is a form of
“internal” radiotherapy where the radiation is guided to the tumor by molecules that
specifically target cancer cells. As in radiotherapy TRT requires an accurate calculation of
the radiation dose to the tumor and surrounding healthy tissues to maximize the success of
killing the tumor and minimize the chances of complications. Current TRT dose calculation
uses a whole tumor/organ approach which is not accurate. The more accurate approach,
called Monte Carlo simulation, requires a long calculation time so it is not practicable in
clinical use. This thesis develops a new dose calculation method, called 3D convolution,
which is faster and has similar accuracy as the MC simulation method.
The accuracy of the 3D convolution method was first tested in the idealized situation of
calculating the dose in a material of the same density surrounding a radiation source. The 3D
convolution results agreed with those obtained with MC simulation. Then dose calculations
in PCa patients were compared. The mean dose in the prostate and healthy organs as
evaluated by the 3D convolution method was 5-7% lower than the MC simulation. The likely
explanation for this discrepancy is that MC simulation is able to account for density
variations within the human body whereas the 3D convolution method assumes no density
variations.

iii

Co-Authorship Statement
Chapter one and two. I did the literature review, wrote the first draft of the chapters, and
revised the chapters with comments and suggested changes from my supervisors.
Chapter three was the validation of the in-house Monte Carlo (MC) simulation code,
egs_mird. I designed the tests with help from my supervisors and Dr. Martin Martinov who
wrote the MC code. The test involving comparing egs_mird DPKs with those from literature
was included in the manuscript “Fast beta‐emitter Monte Carlo simulations and full patient
dose calculations of targeted radionuclide therapy: introducing egs_mird”. Published in
Medical Physics. Published online July 15, 2022. doi:10.1002/mp.15786. I interpreted the
results of the tests and wrote the first draft of this chapter and revised the chapter under the
guidance of my supervisors.
Chapter four compares the dose distributions of prostate cancer patients calculated by the
convolution method and egs_mird. The patient studies were from an archived database
generated by the clinical trial (NCT04009174) on men with untreated, biopsy-proven,
localized prostate cancer. The study protocol was approved by the institutional Research
Ethics Board. I analyzed the studies to obtain the required information for dose calculations
as described in this Chapter. I interpreted the results of the dose comparisons and wrote the
first draft of this chapter and revised the chapter under the guidance of my supervisors.

iv

Acknowledgments
My thesis would not have been possible without the direct and indirect guidance and support
of many individuals.
First and foremost, I am highly and forever indebted to my supervisors, Dr. Ting-Yim Lee
and Dr. George Hajdok for their profound support and guidance throughout my study. The
sacrifice of your time in meetings and conversations were vital in inspiring me and
challenging my mind. You taught me how to interpret results with cautious optimism,
communicate effectively and think critically, which have made me a better scientist. It was
indeed a privilege to work with you.
This endeavor would not be possible without my advisory committee members, Dr. Rowan
Thomson, Dr. Stewart Gaede, and Dr. Martin Martinov. Thank you for your guidance and the
value of your expertise invested in me during this research. It was wonderful to have you as
my advisory committee member. My experience with Monte Carlo and its applications
would have been limited without Dr. Martin Martinov's input. I`m indeed grateful.
Thanks to my lab members, Dr. Xiaogang Chen, Kevin Jaeyoung Chung, Heather Young,
Danny De Sarno, Olivia Tong, Dr Thanh Tai Duong and Anne Leaist for the insightful
discussions and for making my time at Robarts enjoyable. To Heather Young, thank you for
helping me with image segmentation and mentorship. Words cannot express my gratitude to
Anne Leaist. Thank you for your profound help with all the administrative work in the lab.
You made my graduate career so much easier by helping me to focus on my research.
To the Medical Biophysics graduate chair, Dr. Charles Alexander McKenzie, I am grateful
for your mentorship and support. Thanks to Kathleen Petts and Elizabeth Oliveira for helping
me with administrative work in the department. Thanks to Dr. Udunna Anazodo and Dr
Francis Fezeu for their mentorship and support.
Most importantly, I thank my family and friends. To my mom and siblings, thank you for
your constant love, encouragement and support during challenging times. Lastly, I thank
God Almighty for always being with me.
v

Table of Contents
Abstract ............................................................................................................................... ii
Lay Abstract ....................................................................................................................... iii
Co-Authorship Statement................................................................................................... iv
Acknowledgments............................................................................................................... v
Table of Contents ............................................................................................................... vi
List of Tables ...................................................................................................................... x
List of Figures ................................................................................................................... xii
List of Abbreviations ....................................................................................................... xvi
List of Appendices ......................................................................................................... xviii
Chapter 1 ............................................................................................................................. 1
1 Introduction .................................................................................................................... 1
1.1 Prostate Cancer Epidemiology ................................................................................ 1
1.2 Mechanism .............................................................................................................. 2
1.3 Prostate Cancer Symptoms, Screening and Diagnosis ........................................... 3
1.4 Prostate Cancer Staging and Grading ..................................................................... 4
1.5 Prostate Cancer Imaging Modalities ....................................................................... 8
1.5.1

Computed Tomography .............................................................................. 8

1.5.2

Multiparametric MRI .................................................................................. 9

1.5.3

Positron Emission Tomography/Computed Tomography ........................ 10

1.5.4

PET/MRI ................................................................................................... 11

1.6 Prostate Cancer Treatment Modalities .................................................................. 11
1.6.1

Local Treatment Options .......................................................................... 11

1.6.2

Systemic Treatment Options ..................................................................... 13

1.7 Targeted Radionuclide Therapy ............................................................................ 14
vi

1.7.1

Targeted Radionuclide Therapy: Overview .............................................. 15

1.7.2

Targeted Radionuclide Therapy Radionuclides, Carrier Molecules and
Tumor Targeting ....................................................................................... 18

1.7.3

Targeted Radionuclide Therapy for Prostate Cancer ................................ 19

1.7.4

TRT for Prostate Cancer: Current Limitations and Possible Solutions .... 22

Chapter 2 ........................................................................................................................... 27
2 Dose Calculation Methods in Targeted Radionuclide Therapy ................................... 27
2.1 Approaches to Dosimetry in Targeted Radionuclide Therapy ............................. 27
2.2 Definition: Absorbed Dose ................................................................................... 28
2.3 Dose Calculation Method ..................................................................................... 29
2.3.1

Organ S-value Dosimetry ......................................................................... 29

2.3.2

Dose Point Kernel Convolution ................................................................ 31

2.3.3

Full Monte Carlo Simulation .................................................................... 32

2.3.4

Quantification of Time-Integrated Activity from PET/SPECT Images ... 36

2.4 Thesis Objectives and Outline .............................................................................. 39
2.4.1

Chapter 3: egs_mird MC code validation ................................................. 39

2.4.2

Chapter 4: Three-dimensional Voxel-level Dose Point Kernel Convolution
Code .......................................................................................................... 40

2.4.3

Chapter 5: Conclusion and Future Direction ............................................ 40

Chapter 3 ........................................................................................................................... 41
3 egs_mird Validation ..................................................................................................... 41
3.1 egs_mird Monte Carlo Code ................................................................................. 41
3.1.1

egs_mird Monte Carlo Code ..................................................................... 41

3.2 Methods................................................................................................................. 46
3.2.1

Internal Consistency Test .......................................................................... 46

3.2.2

External Consistency Test......................................................................... 48

3.3 Results ................................................................................................................... 49
vii

3.3.1

Internal Consistency Test .......................................................................... 49

3.3.2

External Consistency Test......................................................................... 52

3.4 Discussion ............................................................................................................. 54
3.5 Conclusion ............................................................................................................ 56
Chapter 4 ........................................................................................................................... 57
4 Three-Dimensional Voxel-Level Dose Point Convolution Code ................................ 57
4.1 Motivation ............................................................................................................. 57
4.2 Methods................................................................................................................. 58
4.2.1

Dynamic PET and CT Study..................................................................... 58

4.2.2

Conversion of PET and CT Data for DPK Convolution and Monte Carlo
Simulation ................................................................................................. 59

4.2.3

Absorbed Dose Calculation Comparison between Analytical Calculation,
DPK Convolution and Monte Carlo Simulation ....................................... 61

4.2.4

Patient-Specific 3D Dose Convolution and Monte Carlo Simulation ...... 62

4.3 Results ................................................................................................................... 64
4.3.1

Absorbed Dose Comparison between Analytical Calculation, DPK
Convolution and Monte Carlo Simulation ................................................ 64

4.3.2

Patient-Specific 3D Dose Convolution and Monte Carlo Simulation ...... 67

4.4 Discussion ............................................................................................................. 86
4.5 Conclusion ............................................................................................................ 89
Chapter 5 ........................................................................................................................... 90
5 Conclusion and Future Directions ................................................................................ 90
5.1 Summary ............................................................................................................... 90
5.2 DPK Convolution Density Correction .................................................................. 91
5.3 Estimation of Biological Effective Dose .............................................................. 92
5.4 Estimation of Time-Integrated Activity ................................................................ 93
5.4.1

Exponential Extrapolation ........................................................................ 94
viii

5.4.2

From Kinetic Modelling ........................................................................... 94

References ......................................................................................................................... 96
Appendices ...................................................................................................................... 116
Curriculum Vitae ............................................................................................................ 124

ix

List of Tables
Table 1.1: Prostate cancer stage grouping by TNM classification.38–42 .................................... 5
Table 1.2: The Gleason grading system for prostate cancer.38–42 ............................................. 7
Table 1.3: Prostate cancer stage groups.38–42 Abbreviations: T – Primary tumor; N -Regional
lymph node; M – Distant metastasis; PSA - Prostate-specific antigen; G - Gleason group. .... 7
Table 1.4: List of TRT clinical trials for the treatment of different neuroendocrine tumors. . 17
Table 1.5: List of radionuclides used in targeted radionuclide therapy, their half-life, particle
energy, maximum particle energy, and penetration range in tissue.94,118–121 .......................... 19
Table 1.6: List of radiolabeled ligands used for PSMA targeting in targeted radionuclide
therapy for prostate cancer. ..................................................................................................... 21
Table 1.7: List of clinical trials for the treatment of prostate cancer. ..................................... 25
Table 3.1: Cristy and Eckermann's elemental composition.237 ............................................... 48
Table 3.2: Energy deposition profile of 177Lu in volumes of different sizes as estimated from
DPK of 1 mm and 2 mm voxel resolution. ............................................................................. 50
Table 3.3: egs_mird Monte Carlo simulation using 1 mm and 2 mm voxel resolution of total
energy deposition from a 177Lu radionuclide source. For comparison, energy deposited for a
simulation with no transport is also included. ........................................................................ 51
Table 3.4: Simulations of total energy deposition of monoenergetic 120 keV and 500 keV
photon and monoenergetic 500 keV electron in (65 cm)3 and (100 cm)3 phantom sizes. ...... 51
Table 3.5: Theoretical calculation to estimate the absorbed dose from electron capture and
Auger electron not considered in vxlPen MC simulation of the decay of 177Lu radionuclide
source. ..................................................................................................................................... 56
Table 4.1: The media assignment scheme used to assign the media described in Table 4.2 to
different structures defined for the patient CT. ....................................................................... 60
x

Table 4.2: The density and atomic composition of all elements used in this work with their
accompanying source in the literature. DPK Tissue also includes trace amounts of Mg, Si, Fe,
Zn, Rb, Zr, and Pb not listed on the table. .............................................................................. 60
Table 4.3: Average area under the DVH curve for the prostate and other organs at risk like
the rectum, and bone marrow for the different dose calculation methods. ............................. 74
Table 4.4: Total dose under the DVH curve for the prostate and other organs at risk like the
rectum, and bone marrow. ...................................................................................................... 79
Table 4.5: Area under the DVH curve for the prostate and other organs at risk like the
rectum, and bone marrow for the different dose calculation methods. ................................... 85

xi

List of Figures
Figure 1.1: An illustration of the different Gleason grades. (Reprinted with permission from
Macmillan Publishers Ltd: Modern Pathology43, copyright (2004).) ....................................... 6
Figure 2.1: (A) DPK formalism and (B) Voxel S value formalism in the distribution of
energy from radionuclide. ....................................................................................................... 31
Figure 2.2: Time-integrated activity quantification workflow ............................................... 37
Figure 3.1: Schematic diagram of DPK phantom. The source, 177Lu radionuclide source was
positioned at the center voxel. The DPK phantom was filled with prostate media with a
density of 1.03 g/cm3. ............................................................................................................. 47
Figure 3.2: 177Lu DPKs generated with egs_mird for 1 mm (in blue) and 2 mm (in red) voxel
resolution................................................................................................................................. 50
Figure 3.3: Comparison of 90Y DPKs generated using egs_mird (black circle) to other DPKs
from the literature. .................................................................................................................. 53
Figure 3.4: Comparison of 131I DPKs generated using egs_mird (black circle) to other DPKs
from the literature. .................................................................................................................. 53
Figure 3.5: Comparison of 177Lu DPKs generated using egs_mird (black circle) to other
DPKs from the literature. A magnified scale of the DPK profile at the center voxel is shown.
................................................................................................................................................. 54
Figure 4.1: 3D Fast Fourier Transform dose convolution workflow ..................................... 63
Figure 4.2: Dose point kernel (DK) of a radionuclide source emitting a 500 keV
monoenergetic electron plotted along the x-(green), y-(blue) and z-axis (pink) for no
radiation transport. The profiles along the x- and the y-axis overlap completely. ................. 65
Figure 4.3: Dose profiles of the absorbed dose distributions in a phantom containing a 500
keV monoenergetic electron source at a uniform voxel TIA of 1 Bq.s calculated by DPK
convolution and noVR MC with no radiation transport. ........................................................ 65
xii

Figure 4.4: DPK with radiation transport of a 500 keV monoenergetic electron source plotted
along the x-(green), y-(blue) and z-axis (pink). ...................................................................... 66
Figure 4.5: Dose profiles of the absorbed dose distributions in a phantom containing a 500
keV monoenergetic electron source at a uniform voxel TIA of 1 Bq.s calculated by DPK
convolution and noVR MC with radiation transport. ............................................................. 67
Figure 4.6: A cross-sectional slice from the [18F]DCFPyL PET/CT study of a patient (IGPC02-036) showing (a) media assignment, (b) density map, and TIA map for (c) full activity
and (d) noCalc denoting no activity in calcifications. ............................................................ 68
Figure 4.7: Dose map from simulated 177Lu TRT of the same cross-sectional slice as Figure
4.7. in U = µGy·GBq−1·s−1 units. The dose maps were computed using DPK convolution
(top) and noVR egs_mird simulation (middle), an egs_mird simulation with tracklength
scoring (bottom). The left and right images show dose maps with (full) and without (noCalc)
activity in the calcifications, respectively. A magnified image of the prostate is shown for
each dose map. ........................................................................................................................ 69
Figure 4.8: X- and Y-dose profile of the density corrected DPK convolution (red) and noVR
MC (blue) dose maps calculated using full activity TIA in calcifications of Figure 4.8 are
shown here. The DPK simulation-derived uncertainties were convolved with the timeintegrated activity to generate error bars on the DPK plot while noVR uncertainties were
derived from MC simulation. The black arrows point to calcified regions. ........................... 70
Figure 4.9: (A) X-dose profile of the density corrected DPK convolution (red) and noVR MC
(blue) dose maps with no activity in calcifications. (B) Y-dose profile of the same dose maps
as (A). (C) X-dose profiles of density corrected DPK convolution maps with full (blue) and
no (red) activity in the calcifications. (D) Y-dose profiles of the same dose maps as in (C).
The black arrows point to calcifications with no assumed activity in them. .......................... 71
Figure 4.10: Comparison of (A) X- and (B) Y-dose profiles in DPK convolution dose maps
with (blue) and without (red) density correction. The maps were generated with full activity
in the calcifications. The black arrows point to the calcified region. ..................................... 72

xiii

Figure 4.11: Dose-volume histograms derived from dose distribution calculated with density
corrected DPK convolution calculations, noVR MC and TL MC using TIA matrices with full
and no activity in calcifications for (A) prostate, (B) bladder, (C) rectum, and (D) bone
marrow. ................................................................................................................................... 73
Figure 4.12: Organ-level absorbed doses estimated using DPK convolution with and without
density correction compared to noVR MC. ............................................................................ 74
Figure 4.13: A cross-sectional slice from the [18F]-DCFPyL PET/CT study of a patient
without calcifications in the prostate showing (a) media assignment, (b) density map, and (c)
TIA map. ................................................................................................................................. 75
Figure 4.14: Dose maps of a patient without calcification in the prostate from simulated 177Lu
TRT. The maps were computed using DPK convolution (left) and noVR egs_mird simulation
(middle), an egs_mird simulation with tracklength scoring (right). A magnified image of the
prostate is shown for each dose map. Dose values are expressed in units of U =
µGy·GBq−1·s−1. ....................................................................................................................... 75
Figure 4.15: (A) The dose map of a cross-sectional slice superimposed on its corresponding
CT image with distance scales shown for the x- and y-axis. The x-dose profiles of the 177Lu
DPK convolution (red) and noVR MC (blue) are shown in (B) and the y-dose profiles in (C).
The error bars on the dose profiles were obtained with the uncertainties in the dose maps.
These uncertainties were calculated as described in the text. ................................................. 76
Figure 4.16: The difference in dose profiles between DPK convolution maps calculated using
density correction (blue) and without density correction (red) using the activity TIA map
from [18F]DCFPyL. The dose is in units of µGy·GBq−1·s −1.................................................. 77
Figure 4.17: Dose volume histograms from dose distributions calculated by DPK convolution
and MC with noVR and with TL dose scoring. There were differences between the DPK
convolution and MC DVHs but the MC DVHs were the same. ............................................. 78
Figure 4.18: Organ-level absorbed doses estimated using DPK convolution with and without
density correction compared to noVR MC. ............................................................................ 79

xiv

Figure 4.19: A cross-sectional slice from the [18F]FCH PET and CT study of a patient (IGPC02-028) showing (a) media assignment, (b) density map, and TIA map for (c) full activity
and (d) noCalc denoting no activity in calcifications. ............................................................ 80
Figure 4.20: Dose map from simulated 177Lu TRT of the same cross-sectional slice as Figure
4.19 in U = µGy·GBq−1·s−1 units. The dose maps were computed using DPK convolution
(top) and noVR egs_mird simulation (middle), an egs_mird simulation with tracklength
scoring (bottom). The left and right images show dose maps with (full) and without (noCalc)
activity in the calcifications, respectively. A magnified image of the prostate is shown for
each dose map. ........................................................................................................................ 81
Figure 4.21: X- and Y-dose profile of the density corrected DPK convolution (red) and noVR
MC (blue) dose maps with full activity in calcifications of Figure 4.19 are shown here. The
DPK simulation-derived uncertainties were convolved with the time-integrated activity to
generate error bars on the DPK plot while noVR uncertainties were derived from MC
simulation................................................................................................................................ 82
Figure 4.22: (A) X-dose profile of the density corrected DPK convolution (red) and noVR
MC (blue) dose maps with no activity in calcifications. (B) Y-dose profile of the same dose
maps as (A). (C) X-dose profiles of density corrected DPK convolution maps with full (blue)
and no (red) activity in the calcifications. (D) Y-dose profiles of the same dose maps as in
(C). The black arrows point to calcifications with no assumed activity in them. ................... 83
Figure 4.23: Comparison of (A) X- and (B) Y-dose profiles in DPK convolution dose maps
with (blue) and without (red) density correction. The maps were generated with full activity
in the calcifications. The black arrows point to calcification. ................................................ 84
Figure 4.24: Dose-volume histograms derived from dose distribution calculated with density
corrected DPK convolution calculations, noVR MC and TL MC using TIA matrices with full
and no activity in calcifications for (A) prostate, (B) bladder, (C) rectum, and (D) bone
marrow. ................................................................................................................................... 85
Figure 4.25: Organ-level absorbed doses estimated using DPK convolution with and without
density correction compared to noVR MC. ............................................................................ 86
xv

List of Abbreviations
3D

Three-dimensional

ADT

Androgen deprivation therapy

AS

Active surveillance

BED

Biological effective dose

BMD

Bone mineral density

CI

Confidence interval

CRPC

Castration recurrent prostate cancer

CT

Computed tomography

DNA

Deoxyribonucleic acid

DPK

Dose point kernel

DRE

Digital rectal exam

DVH

Dose volume histogram

DWI

Diffusion-weighted images

EBRT

External beam radiotherapy

FCH

Fluorocholine

FDA

Food and Drug Administration

FDG

Fluorodeoxyglucose

FFT

Fast Fourier transform

HDR

High dose rate

Gy

Gray

HDR

High dose rate

HU

Hounsfield unit

LDR

Low dose rate

LET

Linear Energy Transfer

MC

Monte Carlo

mCRPC

metastatic castration-resistant prostate cancer

MIRD

Medical internal radiation dose

mp

Multiparametric

MRI

Magnetic resonance imaging

PCa

Prostate cancer

PI-RADS

The Prostate Imaging - Reporting and Data System

PSA

Prostate-specific antigen
xvi

PSMA
RBE
TIA

Prostate-specific membrane antigen
Radiobiological effectiveness
Time-integrated activity

TL

Tracklength

TNM

Tumour-node-metastasis

TRT

Targeted radionuclide therapy

TRUS

Trans-rectal ultrasound

VR

Variance reduction

VSV

Voxel S-value

xvii

List of Appendices
Appendix A: Copyright Agreement ...................................................................................... 116
Appendix B: Dose Point Kernel Input File ........................................................................... 120
Appendix C: egs_mird Input File for Patient simulation ...................................................... 121

xviii

1

Chapter 1

1

Introduction

1.1 Prostate Cancer Epidemiology
Cancer is characterized by abnormal cell division; derived from multipotent stem cells.
But, an alternative hypothesis holds whereby normal stem cells undergo changes and
become malignant.1 Progenitor cells for cancer cells may exhibit the same characteristics
as normal cells.2
The prostate is a small gland located directly below and posterior to the bladder, and is an
essential component of a man's reproductive and urinary systems.3 Prostate cancer is a
disease that has been around for a long time and its history dates back more than a
century. In the early years, prostate cancer was denoted a “rare disease”.4 Many years
later, it has become a common disease in men. According to the Canadian Cancer Society
in 2019, prostate cancer is the most prevalent cancer among Canadian older males
accounting for about 1 in 5 (20%) new cases followed by: lung (13%), colorectal (13%),
bladder (8%) and non-Hodgkin lymphoma (5%) cancers. 10% die from prostate cancer
among other cancers in men.5–7
Risk factors and mortality rate of prostate cancer differ according to geographical areas,
environmental exposure, typical western diets (such as consumption of dairy products, red
and processed meats, high calcium and high-fat diets), age, and genetic susceptibility.8–10

There have also been reports of infections, obesity, metabolic syndrome, sexual behavior,
and lifestyle, such as exercise, affecting the disease.11,12 As compared to other cancers,
the risk of prostate cancer increases with age.6 At age 50, the lifetime chance of
histological evidence of prostate cancer is 42%, but the risk of having a clinically
significant illness is only 9.5%, and the risk of dying from prostate cancer is just
2.9%.13,14 Early-onset prostate cancer is characterized by a small number of genetic
alterations that are mutation-driven. This condition is very favorable for the development
and growth of prostate cancer as small breaks in the genome can make the cells
susceptible to cancer.15
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Research has shown that only 0.6% of people between 35 and 44 years were diagnosed
with cancer, but between 65 and 74 years of age, the prevalence was higher. Malik et al.
found a direct association between age and prostate cancer, as the cancer rate increases
40-fold over the age of 80 compared to age 50. Other studies found contradictory
conclusions about race. A cohort study involving 306,100 patients showed no association
between black ethnicity and disease. However, according to Nettey et al.,16 the frequency
of prostate cancer was higher in black men as compared to other people who were not
black. Their meta-analysis also showed a higher median incidence rate of cancer
19.5/100,000 in the African region compared to Asians, Europeans, or the American
population. Additionally, the registry database which covers 28% of the US population
showed a high incidence of prostate cancer (38.3/100,000 persons per year) in the
African-descents as compared to white (17.3), Asian Americans (11.2/100,000) or
Hispanics (18.9) population.17

1.2 Mechanism
The exact mechanism of prostate cancer is not yet known. However, two plausible
hypotheses are changes in the expression of growth factors or steroid hormones. The
growth and proliferation of healthy prostate tissue and androgen-dependent prostate
cancer are regulated by androgen hormones, such as testosterone, for growth and
survival.18 The growth factors leading to prostate cancer development include: vascular
endothelial growth factor (VEGF), transforming growth factor-β (TGFβ) and insulin-like
growth factors (IGFs), especially IGF-1.19 The prostate is a hormone-sensitive organ, and
its functions are stimulated by the activation of steroid hormones which are responsible
for the initial development of prostate cancer in 70% of cases.20
Testosterone affects genes, called proto-oncogenes, which are responsible for the
encoding of several growth factors and serine proteases, including prostate-specific
antigen (PSA) and protein C.21 Testosterone facilitates the expression of apoptotic genes,
and hence affects the apoptotic processes and stages of cancer. According to Dobbs et al.
estrogen and its receptors play an important role in the development and progression of
prostate cancer. The prostate gland has membrane-associated estrogen receptors, G
protein-coupled receptor 30 (GPR30), and nuclear estrogen receptors.22 The activation of
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estrogen receptor-alpha causes prostate carcinogenesis whereas the GPR30 refers to the
non-genomic action of estrogens.23 So, these may not only affect the receptors, but also
the DNA and mutagenic activity.
A castration-resistant prostate cancer results when androgen-deficient prostate cancer
cells develop alternate pathways to compensate for androgen deficiency.24 Cancer cells
may develop pathways hypersensitive to androgen, which are dependent on low levels of
androgen to grow.25 Other factors contributing to the development of prostate cancer
include chromosomal alterations and altered expression of oncogenes.26

1.3 Prostate Cancer Symptoms, Screening and Diagnosis
In the early stages of prostate cancer, there are generally no signs or symptoms. Patients
may suffer symptoms such as reduced urine flow, urinary incontinence, inability to
urinate, blood in the urine, discomfort or burning sensation during urination, or constant
pain in the lower back, upper thighs, or pelvis as their malignancy progresses.25 These
symptoms are frequently misinterpreted by patients as being innocuous, non-specific, or
comparable to symptoms associated with other less severe diseases. As a result, it is
critical to begin screening for early prostate cancer as soon as possible, because it is
considerably more treatable at this stage.27
Prostate cancer is diagnosed in more than half of the countries of the world, and is the
fifth-largest cause of death in men.28 Men at ≥ 60 of age are often advised to undertake
routine screening, to catch the disease before reaching an advanced stage when symptoms
typically present. Early-stage disease may not require treatment due to its indolent nature.
Approximately 74% of prostate cancers are diagnosed as Stage (I or II) in Canada, which
increases the likelihood of survival (93%) at five years after diagnosis.6 Prostate cancer is
often diagnosed by two screening tests: the digital rectal examination (DRE) and
prostate-specific antigen (PSA) blood test. PSA is a protein secreted by epithelial cells of
the prostate gland. The PSA test measures the level of PSA in the blood. However, PSA
levels can also be raised by benign prostatic hyperplasia, asymptomatic inflammation,
prostatitis (an infected prostate), or simply age.29 The DRE involves the physician
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inserting a gloved finger into the rectum, and palpating the prostate gland to determine
whether it has increased in size.30 In the prostate, tumors commonly develop along the
rectal wall, whereby hard areas or asymmetry may indicate disease.
A pivotal study from 1994 found that a PSA threshold of 4.0 ng/mL was effective in
selecting patients for biopsy to determine whether prostate cancer is present.31,32 A PSA
level of 4–10 ng/mL is considered marginal and indicates a 25% chance of prostate
cancer; while a PSA of more than 10 indicates a risk of more than 50%.33,34 Among the
Canadian Task Force on Preventive Health Care (an independent group of clinicians and
methodologists that recommends primary and secondary disease prevention maneuvers)
investigated the overall effect between the possible benefits and harms of PSA screening
with or without digital rectal examination. The task force concluded that PSA screening
does not reduce mortality among men of any age conclusively, but it carries an increased
risk of harm.35 PSA screening can lead to false-positive results, prostate biopsy harm, and
overdiagnosis.35 There is an increased risk of false-positive results indicating prostate
cancer when there is none due to urinary tract and prostate infections increasing PSA
levels. A biopsy is usually recommended for men with high PSA test results. There are
several complications associated with prostate biopsy, including hematuria, infection,
hospital admission and death. In overdiagnosis, cancer is correctly detected but does not
cause symptoms or death. Thus, the task force recommends that the PSA test be avoided
in the screening for prostate cancer.35 Transrectal ultrasound (TRUS) and multiparametric magnetic resonance imaging (mpMRI)-guided biopsy are two of the most
common methods for detecting prostate cancer.36 In patients with prostate cancer, the
mpMRI had a higher detection rate than TRUS.37 Both TRUS and mpMRI-guided biopsy
utilizes imaging guidance and a needle to remove tissue to detect prostate disease.36

1.4 Prostate Cancer Staging and Grading
A biopsy confirms the presence of prostate cancer, but staging cancer is important to
determine if it has spread beyond the prostate. Additionally, staging helps determine
which treatment to choose based on the risk of disease spread.
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Table 1.1: Prostate cancer stage grouping by TNM classification.38–42
TNM classification
Primary Tumour (T)

Label
TX
T0
T1
T1a
T1b
T1c
T2
T2a
T2b
T2c
T3
T3a
T3b
T4

Regional Lymph
Nodes (N)

NX
N0
N1
N2

N3
Distant Metastasis
(M)

MX
M0
M1
M1a
M1b
M1c

Representation
Primary tumor cannot be assessed
No evidence of primary tumor
Clinically inapparent tumor that is not palpable
Tumor incidental histologic finding in 5% or less of
tissue resected
Tumor incidental histologic findings in more than 5% of
tissue resected
Tumor incidental by needle biopsy found in one or both
sides, but not palpable
Tumor is palpable and confined within the prostate
Tumor involves one-half of one side or less
Tumor involves more than one-half of one side but not
both sides
Tumor involves both sides
Extraprostatic tumor that is not fixed or does not invade
adjacent structures
Extraprostatic extension (unilateral or bilateral)
Tumor invades seminal vesicles
Tumor is fixed or invades adjacent structures other than
seminal vesicles such as the external sphincter, rectum,
bladder, levator muscles, and/or pelvic wall
Regional Lymph Nodes
No positive regional nodes
Metastasis in a single lymph node 2cm or less in the
greatest dimension
Metastasis in a single lymph node 2cm but no more than
5cm in greatest dimension Multiple lymph nodes, none
more than 5cm in greatest dimension
Metastasis in a lymph node no more than 5cm in the
greatest dimension
Distant Metastasis
No distant metastasis
Distant metastasis
Nonregional lymph nodes metastasis
Distant bone(s) metastasis
Other site(s) with or without bone disease
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Figure 1.1: An illustration of the different Gleason grades. (Reprinted with permission
from Macmillan Publishers Ltd: Modern Pathology43, copyright (2004).)
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Table 1.2: The Gleason grading system for prostate cancer.38–42
Gleason group
1

Gleason sum
Gleason Score ≤ 3+3

2

Gleason Score 3+4

3

Gleason Score 4+3

4

Gleason Score 4+4

5

Gleason Score 4+5,
5+4, or 5+5

Representation
The cancerous prostate cells closely resemble
normal prostate cells. The glands are small,
well-formed, and closely packed.
The glands are larger and have more tissue
between them
The tissue still has recognizable glands, but
the cells are darker. Some cells have left the
glands and have started to invade the
surrounding tissue.
The tissue has few recognizable glands. Many
cells are invading the surrounding tissue
The tissue does not have recognizable glands.
There are often just sheets of cells throughout
the surrounding tissue.

Table 1.3: Prostate cancer stage groups.38–42 Abbreviations: T – Primary tumor; N Regional lymph node; M – Distant metastasis; PSA - Prostate-specific antigen; G Gleason group.
Stage
Stage I
Stage IIA
Stage IIB
Stage IIC
Stage IIIA
Stage IIIB
Stage IIIC
Stage IVA
Stage IVB

T
cT1a-c, cT2a
pT2
cT1a-c, cT2a
cT2b-c
T1-2
T1-2
T1-2
T1-2
T3-4
Any T
Any T
Any T

N
N0
N0
N0
N0
N0
N0
N0
N0
N0
N0
N1
N0

M
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1

PSA
<10
< 10
≥ 10 < 20
< 20
< 20
< 20
< 20
≥20
Any
Any
Any
Any

G
1
1
1
1
2
3
4
1 to 4
1 to 4
5
Any
Any

A prostate cancer stage grouping is based on TNM, PSA level, and Gleason group-based
classification.44–46 The TNM stage was developed by the American Joint Committee on
Cancer and International Union Against Cancer.46 It is used to identify the extent of a
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primary tumor (T), affected lymph nodes in the region (N), and to determine whether
metastatic spread has occurred (M).
There are four main stages (I, II, III and IV).47 The early stages of the disease have a
better prognosis than the latter stages. The most advanced stage of the disease is Stage
IV. Only a small portion of the prostate is malignant in Stage I, most cells are benign, and
the gland feels normal. In Stage II, the inspecting finger can feel a lump in the prostate,
and a bigger portion of the prostate is afflicted. The tumor has progressed beyond the
prostate in Stage III, and it has spread to lymph nodes or surrounding organs in Stage IV.
Table 1.1 shows prostate cancer stage grouping by TNM classification and national
comprehensive cancer network (NCCN) staging.
Tumors are graded to make more accurate prognostic predictions. The Gleason Grading
System is the most widely used system for grading tumors based on their appearance
under a microscope.38–42 Table 1.2 and Figure 1.1 illustrate the Gleason grading system
for prostate cancer. A sample of prostate tissue is taken and prepared on slides during the
biopsy procedure. The two most prevalent tumor patterns each receive two grade scores,
which are summed to produce a final Gleason sum. Gleason sums range from 2 to 10 and
Gleason scores range from 1 to 5; with 1 as prostate tissue showing a small sign of
cancer, and 5 as prostate tissue with the most aggressive sign of cancer.48,49 Furthermore,
a tumor with a Gleason sum of 8, 9, or 10 can kill within a short time, whereas a tumor
with a Gleason sum of 6 or below may not make a difference clinically.50,51 Prostate
cancer stage groups are shown in Table 1.3.

1.5
1.5.1

Prostate Cancer Imaging Modalities
Computed Tomography

Conventional computed tomography (CT) is not utilized for the detection and staging of
early prostate cancer because of the poor contrast between different nearby soft tissues
within the pelvic anatomical region and the lack of molecular information.52 Moreover,
CT is still currently recommended in patients with intermediate- to high-risk prostate
cancer and is frequently used to assess nodal and distant metastases.53 In a recent metaanalysis, researchers found that CT scans had a pooled sensitivity of only 42% for
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predicting lymph node involvement.54 The use of CT for prostate cancer is constrained to
distant staging, radiation therapy treatment planning, and PET/CT. CT is not only used to
provide anatomical information when co-registered with positron emission tomography
(PET) but is also used to perform attenuation and scatter correction to improve the quality
of PET images.55

1.5.2

Multiparametric MRI

Multiparametric MRI (mpMRI) is an imaging method for prostate diagnostic procedures
that combines a mix of parametric MRI techniques. Anatomic (T1-weighted and
multiplanar T2-weighted images) and functional sequences (diffusion-weighted imaging
with apparent diffusion coefficient maps and dynamic contrast-enhanced imaging) all are
used in mpMRI.56 The functional sequences improve the MRI's sensitivity and positive
predictive value, while T1-weighted imaging is mainly utilized to assess lymph nodes
and bone structures in the region. T2-weighted imaging is a critical sequence in prostate
mpMRI because it provides a highly defined anatomical image of the prostate gland's
zonal architecture with high soft-tissue contrast.57 The diffusion of water molecules in
tissues can be measured using the diffusion-weighted imaging technique. The dynamic
contrast-enhanced imaging technique is used to analyze contrast agent absorption and
washout by malignant and non-malignant prostatic tissue, thus providing insight into the
microvascular characteristics of tissues.58
The acquisition of high-quality images and the deployment of MRI, in combination with
the interpreting radiologist's expertise, are critical for optimal prostate mpMRI. The
Prostate Imaging Reporting and Data System (PI-RADS) was first proposed in 2012 to
address differences in MRI, imaging acquisition protocols, image interpretation, and
reporting among centers.57 PI-RADS is not designed to increase the overall detection rate
of all types of prostate cancer. Rather, it is designed to detect clinically significant
prostate cancer, which is defined as tumors that are likely to shorten a patient's life
expectancy.57
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1.5.3

Positron Emission Tomography/Computed Tomography

Positron emission tomography/computed tomography (PET/CT) imaging is an imaging
technique that uses a single device to acquire both metabolic and anatomical imaging in a
single diagnostic session. Metabolic imaging is performed using the injection of targeted
radio-labelled tracers. There are now several radiotracers in use, and they have found
applications in various clinical contexts for detecting cancer. The most common PET
tracer is fluorine 18-fluorodeoxyglucose ([18F]FDG), which is a glucose analog that
evaluates glucose transport and metabolism. Researchers have identified and exploited
the Warburg effect as a biomarker for malignancy.59 The Warburg effect is the
metabolism of glucose in cancer cells caused by anaerobic glycolysis. When FDG enters
a cell, it is phosphorylated into FDG-6-phosphate by hexokinase, which is irreversibly
linked to cells.60 FDG uptake is higher in benign hyperplasia, prostatitis, and
inflammation than in normal cells.61,62 Despite widespread usage of [18F]FDG, [18F]FDG
PET/CT is not recommended for use in the diagnosis of prostate cancer.63–65 A study has
demonstrated that [18F]FDG PET/CT have low sensitivity and specificity for the
assessment of prostate cancer due to low tumor-to-background signal and urine excretion
of [18F]FDG.64,66 The urinary excretion of

18

F-FDG masks uptake in the prostate gland

and loco-regional lymph nodes.
The use of carbon-11 (11C)- or fluorine-18 (18F)-labeled choline in imaging is based on an
increase in phosphatidylcholine uptake and turnover in cancer cells, which is an
important component of phospholipids in the cellular membrane.67 The advantage of 11C
over

18

F is it has a lower urine excretion rate, which makes it easier to evaluate the

prostate, and reduces patient radiation exposure.68 Because of its low sensitivity, choline
PET/CT has a role function in prostate cancer diagnosis and initial staging. Instead, it is
mostly used for restaging in cases of biochemical recurrence.68,69 Because prostatespecific membrane antigen (PSMA)-targeting offers so much potential, many institutions
are focusing their efforts on prostate cancer imaging using PET/CT with prostate-specific
membrane antigen (PSMA)-targeting.
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1.5.4

PET/MRI

Higher soft tissue contrast and reduced radiation dosage to the patient are the main
advantages of PET/MRI over PET/CT.70 Major challenges to PET/MRI systems in
clinical practice include MR-attenuation correction and the validation of quantitative
uptake metrics.71 A PET/MRI technique has also shown improvements in

18

F-

fluorocholine PET specificity relative to PET/CT, which is currently limited by the
overlap between malignant and benign diseases. In several studies, PSMA PET/MRI are
used together to identify prostate lesions more effectively.72–76

1.6 Prostate Cancer Treatment Modalities
1.6.1

Local Treatment Options

The standard treatment options for localized prostate cancer include some combination
of: active surveillance, radical prostatectomy, radiotherapy such as external-beam
radiotherapy (EBRT) and brachytherapy, depending on disease staging.

1.6.1.1

Active Surveillance

Active surveillance (AS) is a therapeutic strategy in which patients with NCCN very low
or low-risk or low-grade tumors are constantly monitored and only treated if cancer
progresses. Patients are closely followed to avoid unneeded therapy until disease
advancement or if the patient specifically requests it.77 Patients with clinically localized
prostate cancer, PSA levels less than 10 ng/mL, 2 or fewer positive biopsies, and Gleason
scores of 6 or less are candidates for AS.78 The disadvantages of AS include the presence
of an undetected larger or higher-grade tumor that might have been missed at the time of
biopsy. Furthermore, not all patients can live happily with a tumor that has not been
treated. Based on recently published Toronto experiences with AS, only 30% of 453
patients under AS required and received treatment within 6.8 years of follow-up.78,79
Results were unsuccessful with a PSA relapse-free survival rate of less than 50% at 3
years corresponding to the 30% of the AS group receiving treatment.78 Among men under
AS, erectile dysfunction and urinary obstruction are common disorders.80
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1.6.1.2

Radical Prostatectomy

Radical prostatectomy treatment is very effective in treating early-stage or NCCN
intermediate-risk or selected high-risk prostate cancer. Radical prostatectomy involves
removing the prostate gland, seminal vesicles, and the ampulla of the vas deferens. When
the prostate is removed and the cancer has not spread, the PSA level can be zero. Patients
with properly localized prostate cancer are likely to benefit from radical prostatectomy
treatment due to the possibility of a cure. However, in patients with high-grade prostate
cancer, tumors that have spread outside the prostate gland, and when the tumor is not
completely removed, may not be a complete cure and the disease can recur.50 Among the
risks associated with radical prostatectomy are erectile dysfunction and urine
incontinence, blood clots, anesthetic responses, blood loss, and infection.81

1.6.1.3

External Beam Radiotherapy

Prostate cancer has been treated with external beam radiotherapy since the 1930s, when
low-energy orthovoltage x-rays were used as the radiation source. Modern external beam
radiotherapy uses a megavoltage linear accelerator to deliver ionizing radiation to treat
prostate cancer. The standard dose or dose escalation for external beam radiotherapy is 78
or 79 Gy.50 Hypo-fractionated regiments have become popular over the last several years.
Patients who are considering external beam radiotherapy should have a Gleason score of
7 or a PSA level of 20 ng/mL.50 Side effects of external beam radiotherapy include bowel
problems and urine symptoms including irritative voiding, incontinence, urinary
retention, and erectile dysfunction.82–85

1.6.1.4

Brachytherapy

Brachytherapy treatment is an internal form of radiation therapy that involves inserting
radioactive sources (seeds) directly into the prostate. Radioactive seeds emit radiation
around the area where they are placed, and can be left temporarily for a short time (highdose rate) or permanently for a longer time (low-dose rate).86,87 Transrectal ultrasoundbased volume studies are performed before starting therapy to determine the number of
needles with radioactive seeds, the isotope, and the strength of isotopes required. A
transperineal approach is used for implanting radioactive needles under the guidance of a
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transrectal ultrasound or magnetic resonance imaging.88 For low-dose rate (LDR)
brachytherapy, most patients receive 115 - 120 Gy for palladium-103 (103Pd) or 145 Gy
for iodine-125 (125I) with postoperative dosimetry. Iridium-192 (192Ir) is a seed for highdose-rate (HDR) brachytherapy. HDR delivers about 38 Gy in four fractions.89 Serious
complications can potentially arise with brachytherapy, including superficial urethral
necrosis and rectal fistula.90,91

1.6.2

Systemic Treatment Options

Most patients with localized prostate cancer later develop metastatic disease,
emphasizing the importance of effective treatment strategies at the early stage of the
disease.92 Systemic therapies offer a promising strategy for improving the clinical
outcomes of patients with high-risk localized prostate cancer.92 Systemic therapies,
including androgen deprivation therapy and chemotherapy, are standard-of-care in most
solid and metastatic tumors. Advanced prostate cancer has been known under several
names over the years, including hormone-resistant prostate cancer and androgeninsensitive prostate cancer.93 Castration recurrent prostate cancer (CRPC) has been
introduced with the realization that intracrine/paracrine androgen production plays a
significant role in the resistance of prostate cancer cells to testosterone suppression
therapy.93 Advanced CRPC is a multi-faceted condition that requires multi-disciplinary
care while maintaining a high standard of living, and supportive care remains the top
priority.93

1.6.2.1

Chemotherapy

Chemotherapy refers to the administration of cytotoxic chemicals that kill cells to
eradicate the tumor or, reduce it, and in turn, the symptoms associated with it and
possibly extend a patient's life.94 Cytotoxic drugs are usually given intravenously.
Chemotherapy is a treatment option for prostate cancer and studies have proven its
effectiveness in the palliation of symptoms in patients with metastatic disease.95
Chemotherapy drugs include cabazitaxel, mitoxantrone, taxane, docetaxel and others.96,97
Chemotherapy drugs have shown different toxicity profiles such as neutropenia,
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neutropenic infection, diarrhea, hematuria, peripheral neuropathy, stomatitis, peripheral
edema, alopecia, and nail disorders.97

1.6.2.2

Androgen Deprivation Therapy

Androgen deprivation therapy (ADT) is a hormone-based therapy for patients with
advanced prostate cancers and selected patients with localized prostate cancers. ADT has
been evaluated in clinical trials for patients with metastatic and advanced locoregional
diseases, but the risk-benefit ratio, especially in earlier stages, remains unclear.98
Research has shown that ADT can cause bone, endocrine, sexual, and cognitive
dysfunctions as well as adverse effects on body composition and health.99 ADT increases
the risk of developing diabetes, a cardiovascular event, and a decrease in bone mineral
density (BMD).100,101 ADT studies have shown that BMD declines as early as 6 months
into treatment. BMD decreased by 3% and 2.7% for the lumbar spine and the femoral
neck at 6 months, by 4.6% and 3.9% at 12 months, and by 7.1% and 6.6% at 18 months,
respectively.101 The results of another study showed a mean bone loss of 3.3% at the hip
and 5.3% at the distal radius one year after ADT.101 Before patients begin ADT, they
should be fully informed about the risks and the potential benefits of therapy.

1.7 Targeted Radionuclide Therapy
Targeted radionuclide therapy (TRT) is a systemic treatment just like chemotherapy and
androgen deprivation therapy. It involves the administration of a radioactive substance
into the bloodstream of patients. However, it differs from chemotherapy by specifically
targeting tumor cells and sparing normal tissues with a reduction in potential side effects.
TRT differs from traditional radiotherapy in that radiation is not from an external source.
Rather, it is an internal exposure to radiation from the intravenously administered
radiolabeled targeted molecule. The radionuclide is usually incorporated into a carrier
molecule, forming a magic bullet in Paul Ehrlich’s words, with a high affinity for cancer
cells via receptors, antigens, or enzymes.102 TRT differs from external beam radiotherapy
(EBRT) in that it requires detailed knowledge about tumor biology rather than tumor
location.
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The desired tumoricidal effect of TRT is from ionizing radiation emitted by the
radionuclide. The radionuclide (e.g.,

18

F,

68

Ga) used in SPECT and PET molecular

imaging emits gamma rays which have strong penetrating power in tissue, up to
centimeters. On the other hand, TRT radionuclides emit particulate radiations such as
alpha particles, beta particles, or Auger electrons. These radiations have a lower
penetrating power relative to gamma radiation. Beta particles have a longer range than
alpha particles. Beta particles have a range of tens in cell diameters, but alpha particles
have a much shorter range to destroy cancer cells surrounding the radionuclide. While
particulate radiation is preferred for TRT, only emitted gamma rays can be used for
imaging. This leads to the concept of a ‘theranostic’ pair103,104, where the same targeting
molecule is labeled with a gamma-emitting radionuclide (e.g.,

177

Lu,

131

I) for SPECT

imaging and with a particulate emitting one for TRT.

1.7.1

Targeted Radionuclide Therapy: Overview

Significant advancements have been made in TRT. Initially, this therapeutic technique
started with the use of radioactive isotopes of iodine (131I,

128

I) with a NaI-targeted

molecule in studying thyroid physiology and treatment of thyroid carcinoma.105–107 Other
targeted molecules have been labeled with radioactive iodine and applied in the treatment
of other diseases. Such is the case of

131

I metaiodobenzylguanidine (MIBG) for the

treatment of metastatic and/or recurrent pheochromocytoma or paraganglioma which
eventually led to the Food and Drug Administration (FDA) approval (Azedra ®).108 TRT
applications using

131

I has been used in patients with low-grade and transformed Non-

Hodgkin’s Lymphoma which is usually incurable. The approach utilized

131

I-

tositumomab and unlabeled tositumomab in five clinical trials, which produced a
significant response rate.109
Researchers have also developed an interest in other radionuclides with better physical
characteristics such as the energy of the emitted radiation (e.g., beta particle) and halflife. This led to the use of Yttrium-90 (90Y) which has higher beta energy and a shorter
half-life than

131

I. The higher beta energy is important to treat larger tumors, and the

shorter half-life for the shorter biological half-life of the targeting radiolabeled molecule.
There was no gamma-emitting radioisotope of Yttrium (Y), and this resulted in the
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development of Indium (111In), which was then used to assess the kinetics of the labeled
immunoglobulin.110,111
A list of TRT clinical trials for the treatment of different cancers, radiolabeled ligand and
their treatment doses can be found in Table 1.4. TRT has found application in
neuroendocrine tumors because of the overexpression of somatostatin receptor. This led
to the development of octreotide, an octapeptide, which is a somatostatin receptor ligand
analog. Different radiolabeled analogs of octreotide were developed ranging from
tyrosine-3 octreotide to the different analogs of the

90

123

I-

Y octreotide analog.
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Table 1.4: List of TRT clinical trials for the treatment of different neuroendocrine tumors.

Trial
Identification
NCT04790708

Study
Phase
Not
applicable

No. of
Patients
250

Disease

Radioligand

Treatment Dose

Study Location

Neuroendocrine
Tumors

Lutetium-177
[177Lu]DOTATOC

5 cycles of 3,7 - 5,55 gigabequerel (GBq) of
[177Lu]DOTATOC every 8-10 weeks.
Cumulative activity: 18,5 - 27,75 GBq

University Hospital of
Ferrara, Ferrara, Italy

Yttrium-90
[90Y]DOTATOC

5 cycles of 1,85 - 2,775 GBq of
[90Y]DOTATOC every 8-10 weeks.
Cumulative activity: 9,25 - 13,875 GBq
177
Lu-edotreotide [90Y]DOTATOC. A
maximum of four cycles of 7.5 ± 0.7 GBq
177Lu-edotreotide, each. 4 cycles, 90 days
apart (total duration: 270 days/9 months)
Four administrations of 5,55GBq up to 7,4
GBq [177Lu]DOTATOC administered at 8week intervals.
Experimental: 28 GBq [177Lu]DOTATATE 5
cycles of 5.5 GBq (150 mCi) each, up to the
total cumulative activity of 28 GBq (750 mCi)
[177Lu]DOTATATE Experimental: 22 GBq
[177Lu]DOTATATE 6 cycles of 3.7 GBq (100
mCi) each, up to the total cumulative activity
of 22 GBq (600 mCi) [177Lu]DOTATATE
7.8GBq 177Lu Octreotate (Lutate) given
intravenously (IV) on day 1 every 8 weeks for
4 cycles.
Maximum cumulative [90Y]DOTATOC
activity of 11.1 GBq (300 mCi), divided into 4
cycles (1.8 - 2.8 GBq for each cycle) with an
interval of 6 - 8 weeks between cycles.

NCT03648073

Phase 1,
Phase 2

30

Hepatocellular
Carcinoma

177Lu-edotreotide
PRRT and Everolimus
Other: Amino-Acid
Solution
[177Lu]DOTATOC

NCT04029428

phase 2

150

Neuroendocrine
Tumors

NCT00416949

Early
Phase 1

10

Neuroendocrine
Tumors

[177Lu]DOTATATE

NCT04385992

Phase 2

30

Neuroendocrine
Tumors

177

NCT04194125

Phase 2

25

Neuroendocrine
Tumors

[90Y]DOTATOC

NCT02736500

Phase 1

37

Neuroendocrine
Tumors

Sunitinib and 177LuDOTA0-Tyr3-Octreotate

NCT02358356

Phase 2

72

Midgut and
Pancreatic
Neuroendocrine
Tumors

177

Lu Octreotate (Lutate)

Lu-Octreotate or
LuTate or 177Lu[DOTA0,Tyr3]octreotate
or [177Lu]DOTATATE

Start - End date
(MM/DD/YYYY
July 2, 2018 - June
30, 2023

University of Alabama at
Birmingham Medical Center,
Birmingham, Alabama,
United States
Centrum DiagnostycznoLecznicze Gammed,
Warszawa, Poland
The Holden Comprehensive
Cancer Center, Iowa City,
Iowa, United States

1/30/2019 December 31, 2022

Ospedale San Raffaele,
Milano, Italy

11/29/2019 November 30, 2021

Centrum DiagnostycznoLecznicze Gammed,
Warszawa, Poland

February 1, 2019 January 31, 2022

177Lu-DOTA0-Tyr3-Octreotate or OCLU 7.4
GBq per injection (max: 4 injections) and
Active Comparator: Sunitinib

Giovanni Paganelli, Meldola,
FC, Italy|Lisa Bodei, Milan,
Italy

9/2/2015 - June
2021

4-cycle induction course (23 Gy) and for each
subsequent cycle (6 Gy)

Australia

11/1/2015 December 2020

11/2/2004 - January
1, 2021
10/11/2018 December 2025
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The overall response rate observed with the 90Y octreotide analog was superior to that of
123

I. Despite promising results obtained with the

90

Y analog, the search for alternative

radionuclides continued, which led to the development of lutetium-177 (177Lu). This
radionuclide has lower beta energy and a longer half-life compared to the

90

Y analog.

This suggests that a greater fraction of the beta energy will be absorbed by the target
tissue, and less radiation exposure to the surrounding tissues, is an advantage for smaller
tumors. Also, this radionuclide emits gamma radiation which can be used for imaging
purposes.112–114

1.7.2

Targeted Radionuclide Therapy Radionuclides, Carrier
Molecules and Tumor Targeting

Radionuclides for targeted radiotherapy must possess certain qualities. Radiation emitted
by radionuclides must inflict damage, mainly DNA double-strand breaks, to kill cancer
cells, while minimizing any damage to bystander normal cells. As such, the radionuclide
can be an alpha, beta, or Auger electron emitter, as these types of particles deposit energy
concentrated with higher density than gamma rays, and hence produce more doublestrand breaks. The radionuclide selection however should be selected based on the energy
of the emitted particle, and the tumor size to be treated.115 Table 1.5 shows a list of
radionuclides used in targeted radionuclide therapy, their half-life, particle energy,
maximum particle energy, and penetration range in tissue.
The physical half-life of the radionuclide should correspond to the kinetics of the carrier
in vivo. It should be long enough to accommodate the time of synthesis, delivery to the
site of administration, injection, and residency time within the tumor. The optimum halflife ranges from six hours to seven days although

89

Sr is an exception which has a half-

life of 50 days.116 The preferred TRT radionuclides must also possess a high grade of
chemical purity and be devoid of traces of metal impurities. Finally, a radionuclide must
be able to bind to a wide variety of carrier molecules and its preparation must be costeffective to ensure universal accessibility.117

19

Table 1.5: List of radionuclides used in targeted radionuclide therapy, their half-life,
particle energy, maximum particle energy, and penetration range in tissue.94,118–121
Isotope

Abbreviation Emitted particles

Half-life

Max.
particle
energy
(keV)

Tissue
penetration
depth (mm)

6.65 days
8.02 days
2.67 days
6.89 days
45.6 min
10.0 days
11.43 days
7.2 days
2.8 days
10.6 h

497
971
2280
154
8381
28000
28200
5870
0.35
6051

1.600
2.300
12.000
0.030
0.084
0.061
0.080
0.067
4.000 nm
0.080

β: Beta, γ: Gamma
α: Alpha
EC: Electron capture
Lutetium-177
Iodine-131
Yttrium-90
Terbium-161
Bismuth-213
Actinium-225
Radium-223
Astatine-211
Indium-111
Lead-212

177

Lu
131
I
90
Y
161
Tb
213
Bi
225
Ac
223
Ra
211
As
111
In
212
Pb

β−, Auger, EC
β−/γ
β−
β−/Auger and EC
α/β−
α
α
α
Auger/γ
α,β−, EC

Just as a radionuclide must meet certain requirements, carrier molecules too must also
possess attributes for their use in TRT. This includes high affinity, and specificity for the
target, lack of toxicity or immunogenicity. Most carrier molecules are antibodies and
peptides, which are resistant to self-radiolysis. Carrier molecules should be wellpreserved under storage conditions and when in contact with biological liquids, and pure
chemically, Furthermore, carrier molecules should be simple, cost-effective production
and have a high binding affinity to a variety of radionuclides.117
An ideal TRT target (antigen, receptor, and others) must possess an even expression and
distribution over the entire cell surface of a malignant tumor, and have a low or negligible
expression in normal cells to minimize unwanted side effects and uptake in the cancer
site, with negligible washout from blood flow.117

1.7.3

Targeted Radionuclide Therapy for Prostate Cancer

Advancements have been continuously made in the treatment of prostate cancer. The 5year survival rate for local and regional prostate cancer is approximately 98%.122
However, the rate drops to 30% for patients with metastases, despite advances in current
treatment options such as surgery, hormone therapy, anti-androgen therapy, and
chemotherapy.122 Thus, the need for other therapeutic choices, like TRT are needed.
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In 1987, Horoszewicz et al. discovered a new type II transmembrane enzymatic protein
marker on the prostate carcinoma cell line called LNCaP.123 This marker was later called
prostate-specific membrane antigen (PSMA). PSMA is overexpressed in prostate cancer
cells and can be detected in the serum of patients. PSMA is overexpressed in 90% to
100% of prostate cancer cases, and it correlates highly with disease progression, with
high PSMA expression in hormone-resistant tumors and metastatic disease.124 PSMA is
an excellent target for diagnostic imaging and therapy.125 PSMA inhibitors or ligands
have been developed based on small peptide molecules modified with urea and labeled
with different radionuclides.126–128 Diagnostic radionuclides include

99m

Tc and

111

I for

single-photon emission computed tomography (SPECT) and PET isotopes (68Ga, 18F and
89

Zr), while therapeutic radionuclides include

177

Lu,

225

Ac,

131

I and

90

Y.129 The list of

radiolabeled ligands used for PSMA targeting in targeted radionuclide therapy for
prostate cancer is reported in Table 1.6. These radiolabeled targeted tracers are
administered intravenously, and accumulate at the tumor sites from binding to PSMA.
The preliminary results of PSMA-targeted radionuclide treatment have accelerated
preclinical research into potential clinical studies. A list of TRT clinical trials using
PSMA-targeting is shown in Table 1.7. PSMA has been found to possess an intracellular
and extracellular epitope for an antibody. In vivo characterization of the intracellular
epitope of PSMA has been done with a 7E11 monoclonal antibody.130 In vitro
characterization (pharmacokinetics, biodistribution, affinity, and specificity) has been
carried out using murine monoclonal antibodies J415, J533, and J591, of which J591 was
the most promising.131

90

Y and

177

Lu were labeled J591. Subsequently,

90

Y and

177

Lu

were labeled DOTA-J591 and were evaluated in nude mice with human prostate cancer
xenografts. Both

90

Y and

177

Lu labeled J591 were found to decrease tumor size and

prolong survival.130,132 Clinical trials were conducted on

177

Lu and 90Y radiolabeled J591

to compare their efficacy and hematological toxicity. The
preferred candidate. Even though

90

177

Lu was chosen as the

Y had a significant antitumor effect,

90

Y was not

chosen because had hematological adverse effects.133–135
The Food and Drug Administration (FDA) has approved

18

F labeled PSMA ligand such

as 3-(3-[1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-pentyl]-ureido)-pentanedioic
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acid, commonly called [18F]DCFPyL, to be used for imaging prostate cancer.136
[18F]DCFPyL produced high image quality and demonstrated excellent sensitivity when
imaging small prostate lesions.137
Table 1.6: List of radiolabeled ligands used for PSMA targeting in targeted radionuclide
therapy for prostate cancer.
Ligand
PSMA-617

PSMA-11
PSMA-1007,
DCFPyl
PSMA-I&T

MIP-1095
MIP-1072
CTT1057
FSU-880
JK-PSMA-7
MIP-1404/-1405
PSMA I&S
CTT1400
AlF-PSMA-11
rhPSMA-7.3
RPS-027
DCIBzL
CTT1402

Radionuclides
Lutetium-177
Actinium-225
Indium-111
Gallium-68
Yttrium-90
Gallium-68
Fluorine-18
Fluorine-18
Lutetium-177
Actinium-225
Indium-111
Gallium-68
Iodine-123
Iodine-131
Iodine-123
Fluorine-18
Fluorine-18
Fluorine-18
Technetium-99m
Technetium-99m
Lutetium-177
Fluorine-18
Fluorine-18
Iodine-131
Astatine-211
Iodine-123
Iodine-131
Lutetium-177

Radioligand
[177Lu]PSMA-617
[225Ac]PSMA-617
[111In]PSMA-617
[68Ga]PSMA-617
[90Y]PSMA-617
[68Ga]PSMA-11
[18F]PSMA-1007
[18F]DCFPyl
[177Lu]PSMA-I&T
[225Ac]PSMA-I&T
[111In]PSMA-I&T
[68Ga]PSMA-I&T
[123I]MIP-1095
[131I]MIP-1095
[123I]MIP-1072
[18F]CTT1057
[18F]FSU-880
[18F]JK-PSMA-7
[99mTc]MIP-1404-1405
[99mTc]PSMA I&S
[177Lu]CTT1400
[18F]AlF-PSMA-11
[18F]rhPSMA-7.3
[131I]RPS-027
[211At]RPS-027
[123I]DCIBzL
[131I]DCIBzL
[177Lu]CTT1402

References
138
139
140
141
142
143
144
145,146
147
148
149
150
151
151
152
153
154
155
156
157
158
159
160
161
161
157
162
163
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Also,

68

Ga-labelled PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11),

shows outstanding affinity to PSMA and, a highly selective uptake in imaging prostate
cancer, lymph node metastases and distant metastases are available and approved by
FDA December 2020.164,165

68

Ga-PSMA PET/CT has been shown to be able to detect

prostate carcinoma relapses and metastases with significantly improved contrast
compared to [18F]FCH PET/CT.166
The VISION clinical trial (NCT03511664) is a randomized phase 3 clinical trial of
[177Lu]PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic
castration-resistant prostate cancer that were previously treated with at least one
androgen-receptor-pathway inhibitor and one or two taxane regimens and who had
PSMA-positive gallium-68 [68Ga]PSMA-11 positron-emission tomographic-computed
tomographic scans.167 All patients receive a fixed amount of 7.4 gigabequerels (GBq) of
[177Lu]PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles
regardless of their body weight.167 [177Lu]PSMA-617 increased imaging-based
progression-free survival and overall survival when added to standard care. Compared to
standard care, imaging-based progression-free survival increased from 3.7 to 8.7 months
with a decrease in the hazard ratio for death at 0.40; 99.2% confidence interval [CI] of
0.57 to 0.29, P<0.001. The overall survival increased with a median from 11.3 months to
15.3 months with a decrease in the hazard ratio for death at 0.62; 95% CI, from 0.74 to
0.52 with P<0.001.167
Therapeutic improvement can be achieved by personalizing TRT treatments based on a
patient's body mass and dosimetry.

1.7.4

TRT for Prostate Cancer: Current Limitations and Possible
Solutions

TRT has demonstrated promising outcomes in the treatment of PCa and has advantages
including target (PSMA) specificity, therapeutic efficacy, low toxicity to normal
surrounding healthy tissues, locoregional control, and excellent palliation of
symptoms.168 However, the challenges that come with TRT include the isolation of
patients, the limited availability of radiopharmaceuticals and isolation beds, and the
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storage of radioactive waste. To achieve the goals of TRT, a multidisciplinary approach
is required, including the design and production of carrier molecules and radionuclides.168
Radionuclides have to be shipped in from production sites at a distance from cancer
centers with transport issues to be resolved. To produce therapeutic radionuclides, more
powerful accelerators are needed with higher energy and complexity than the cyclotrons
available in Positron emission tomography (PET) centers. Even the smaller cyclotrons
available at PET centers are expensive and not readily available at some locations, but
when it comes to larger cyclotrons, things get even more complicated.169,170
For PCa, complications from TRT are generally limited to the haematopoietic tissue and
serious side effects are observed. According to published studies, 91% of patients
receiving [177Lu]PSMA-617 and 100% of patients receiving [225Ac]J591 experienced at
least one adverse event, such as pain, fatigue, dry mouth, nausea, and hematologic
toxicity.171,172

177

Lu PSMA therapy has been associated with low-grade toxicities in all

published studies:173 about 30% of men experience dry mouth after treatment. Fatigue is a
common side effect for up to 25% of men treated. There has also been some nausea
reported in up to 10% of men, particularly during the first 24–48 hours following
injection. As of now, no studies have reported renal toxicity, although it seems likely that
this would be a longer-term complication if it were to occur.174,175 It has been reported
that men with a high burden of skeletal metastases and borderline bone marrow function
may develop haematological toxicity after

177

Lu PSMA therapy. This is more of an

innocent bystander effect than a direct radiation effect on bone marrow.176 A bystander
effect is a biological effect (response) that occurs when non-irradiated neighbors (cells)
respond to radiation. These biological responses include DNA damage, mutation, and
apoptosis. 10%–25% of males with substantial bone metastases had haemoglobin or
platelet levels that dropped by Grade 1–2. No signs of marrow damage/toxicity were
present in men with low amounts of skeletal metastases.176
Dosimetry calculations are likewise required for individual patients. Since its
establishment in the 1950s, TRT has been concerned with issues of precise absorbed dose
calculation.177 Mainly because the distribution of the radiopharmaceutical in the target is
non-uniform, calculating the dose delivered to a target remains difficult.178 The FDA

24

approved the MIRD schema for absorbed dose calculation of radiotracers used in TRT,
but it is not patient-specific.177
Patients with metastatic castration-resistant prostate cancer (mCRPC) may benefit from
TRT with [177Lu]PSMA-617. Paganelli et al.,179 conducted a prospective single-arm,
open-label phase II study to determine the safety and initial response to a minimal
effective injected activity/cycle of [177Lu]PSMA-617 in mCRPC patients. MIRD
formalism (OLINDA/EXM software, v 1.0) was used to calculate the adsorbed dose. A
unit-density sphere model was employed for submandibular and lacrimal glands and
tumor lesion evaluation, while an adult male phantom was used for kidney, liver, red
marrow, and whole-body assessment. This dose calculation method is limited for reasons
discussed later (see §2.3.1). More accurate dosimetry of other ligands or other
radionuclides can be re-evaluated to adjust the treatment protocol to minimize treatment
complications.180 Improved patient-specific absorbed dose estimations will lead to better
toxicity control and clinical outcomes for prostate cancer and other solid tumors in the
future. The goal of this thesis is to develop a patient-specific absorbed dose calculation
method to address the TRT dosimetry challenges.
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Table 1.7: List of clinical trials for the treatment of prostate cancer.
Trial
Identification

Study Phase

No. of
Patients

Disease

Radioligand

Treatment Dose

Study Location

Start - End date
(MM/DD/YYYY

NCT04597411

Phase 1

30

Prostatic Neoplasms,
Castration-Resistant

[177Lu]PSMA-I&T

Single dose 2.0-8.0 GBq treated once
every 8-12 weeks.

April 1, 2021 February 20, 2023

NCT03874884

Phase 1

52

Metastatic Castration
Resistant Prostate
Cancer

[177Lu]PSMA-617

Patients received fixed 7.4 GBq of
lutetium Lu 177-PSMA-617 every 6
weeks

NCT04796467

Early Phase 1

30

Prostate Cancer

[177Lu]PSMA-617,
[177Lu]J591 and
[68Ga]PSMAHBED-CC

NCT04188587

Phase 2

30

Metastatic
Castration-resistant
Prostate Cancer

[177Lu]PSMA-617

[177Lu]PSMA-617 [1.85 GBq (50
mCi) - 9.25 GBq (250 mCi)] x2
doses, 2 weeks apart, [177Lu]J591
[1.35 GBq/m2 or 36.5 mCi/m2] x2
doses, 2 weeks apart, [68Ga]PSMAHBED-CC [185 ±74 MBq or 5 ±2
mCi]
5 GBq of 177Lu-PSMA in 2 cycles,
separated by 6 weeks.

St. Vincent's Hospital Research
Office-Translational Research Center,
Darlinghurst, Australia|Steve Biko
Hospital-Department of Nuclear
Medicine, Pretoria, South Africa
St Vincent's Hospital Sydney,
Sydney, New South Wales,
Australia|Peter MacCallum Cancer
Centre, Melbourne, Victoria,
Australia
Peking Union Medical College
Hospital, Beijing, Beijing, China

Nanjing First Hospital, Nanjing,
Jiangsu, China

January 1, 2019 August 2020

NCT03805594

Phase 1

43

Metastatic Prostate
Carcinoma Prostate
Adenocarcinoma
Stage IV

[177Lu]PSMA-617
and [68Ga]PSMAHBED-CC

[177Lu]PSMA-617 [50mCi
(1.85GBq) - 300mCi (11.1GBq)]
intravenous X2 doses, 2 weeks apart
(Visit 1 and 2) [68Ga]PSMA-HBEDCC [5 ±2mCi or 185 ±74MBq]
intravenous during screening and at
12 weeks with standard imaging

University of California, San
Francisco, San Francisco, California,
United States

January 15, 2019 April 19, 2022

NCT03545165

Phase 1 and
Phase 2

6

Prostate Cancer

[177Lu]PSMA

177

Weill Cornell Medical College, New
York, New York, United States

April 18, 2018 July 15, 2020

Lu-PSMA 3.7-5-5 GBq
Intravenous Slowly in 15-30 ' Day 1/
every 8-12 weeks Four cycles every
8-12 weeks

July 9, 2019 October 2022

October 1, 2020 October 1, 2022
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NCT04430192

Phase 1 and
Phase 2

20

Prostatic Neoplasms

[177Lu]PSMA-617

6-8.5GBq once every 6 weeks until
progressive disease, prohibitive
toxicity or a maximum of 6 cycles.

Peter MacCallum Cancer Centre,
Melbourne, Victoria, Australia

August 6, 2020 June 30, 2023

NCT03042468

Phase 1 and
Phase 2

46

Prostate Cancer

[177Lu]PSMA-617

7.5 GBq (± 10%) 177Lu-PSMA every
6 weeks x 2 cycles. Docetaxel 75
mg/m2 commencing 6 weeks later,
every 3 weeks x 6 cycles

Tulane Cancer Center Clinic, New
Orleans, Louisiana, United
States|Weill Cornell Medical College,
New York, New York, United States

December 2016 September 2022

NCT03454750

Phase 2

210

Metastatic Castration
Resistant Prostate

[177Lu]PSMA-617

7.4GBq (± 10%) every 6 weeks;
maximum 6 cycles

April 19, 2017 August 2022

NCT03392428

Phase 2

201

Cancer of the
Prostate Metastatic
Cancer

177

76 mCi each (equivalent to a 45
mCi/m2 dose in a standard 1.7m2
individual) of [177Lu]DOTArosopatamab, given 14 days apart,
plus best SoC Other Name:
[177Lu]TLX591

NCT04343885

Phase 2

140

Metastatic Hormone
Naive Prostate
Cancer

Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori (IRST),
Meldola, FC, Italy
Australia: Liverpool, St Vincent's,
Royal North Shore, Calvary Mater
Newcastle, Royal Brisbane and
Womens, Royal Adelaide, Austin,
Fiona Stanley, Monash Moorabbin,
Sir Charles Gairdner Hospital, and
Peter MacCallum Cancer Centre
Australia: Liverpool, St Vincent's,
Royal North Shore, Calvary Mater
Newcastle, Royal Brisbane and
Womens, Royal Adelaide, Austin,
Fiona Stanley, Monash Moorabbin,
Sir Charles Gairdner Hospital, and
Peter MacCallum Cancer Centre
BCCA - Vancouver Cancer Centre,
Vancouver, British Columbia, Canada

Diagnostic Nuclear Imaging at
Hollywood Private Hospital, Perth,
Western Australia,
Australia|GenesisCare SJOG Medical
Centre, Murdoch WA, Perth, Western
Australia, Australia

July 15, 2021 June 1, 2026

Lu-DOTArosopatamb

[177Lu]Ludotadipep

Dose is sequentially elevated starting
from a low dose to a high dose (50±5
mCi, 75±8 mCi, 100±10 mCi,
125±13 mCi, 150±15 mCi).

NCT04663997

Phase 2

200

Prostate Cancer

[177Lu]EB-PSMA617

All patients were intravenous
injected with single dose 0.80-1.1
GBq (21.5-30 mCi) of [177Lu]EBPSMA-617, then monitored at 2, 24,
72, 120 and 168 hours post-injection.

NCT04876651

Phase 3

387

Metastatic Prostate
Cancer

[177Lu]DOTATLX591-CHO

Two single IV infusions of 76 mCi
(2.8 GBq) each (equivalent to a 45
mCi/m2 administered activity in a
standard 1.7m2 individual) of
[177Lu]DOTA-TLX591-CHO, given
14 days apart.

January 29, 2018 June 13, 2022

April 21, 2020 April 2024

December 17, 2020
- July 31, 2025
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Chapter 2

2

Dose Calculation Methods in Targeted Radionuclide
Therapy

Direct assessment of absorbed dose distributions in vivo from administered
radiopharmaceuticals in targeted radionuclide therapy is challenging.178 To achieve the
highest possible therapeutic effect, targeted radionuclide therapy aims to deliver the
highest possible absorbed dose to the tumor while sparing healthy tissues.181
Furthermore, patient-specific targeted radionuclide therapy is becoming increasingly
critical to ensure effective treatment, especially with the growth of targeted radionuclide
therapy applications.182 The 3D absorbed dose distribution is important in clinical
practice since low dose regions within the target (tumor) might lead to lesion recurrence,
while high radiation regions can cause tissue necrosis. Studies have shown that normal
organs have varied levels of radiation tolerance and are exposed to non-uniform dose
distributions, resulting in a range of toxicities.183

2.1 Approaches to Dosimetry in Targeted Radionuclide
Therapy
Dosimetry protocol in radionuclide therapy requires the estimation of dose from each
treatment cycle. For dosimetric calculations, quantitative imaging, such as single-photon
emission computed tomography (SPECT) or positron emission tomography (PET) is used
to estimate non-invasively the 3D activity distribution of the therapeutic agent in a patient
including the blood compartment at regular intervals over the residence time of the
radionuclide.184,185 This residence time can be several weeks depending on the physical
and biological half-life of the radionuclide and targeting molecule respectively.
PET has a better diagnostic accuracy compared to SPECT because PET has a higher
sensitivity (i.e., the ability to detect and record a higher percentage of the emitted events)
than SPECT. SPECT needs physical collimators to reject scattered photons or photons
that are not within a small angular range resulting in lower sensitivity.186 The nature of
positron annihilation allows the emission of two opposite annihilation photons at the
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same event. Thus, physical collimators are not needed, but rather a coincidence-detection
which allows a much larger angle of acceptance at each detector position, thereby
significantly increasing the gain in sensitivity for PET. SPECT has more issues with
artifacts and attenuation compared to PET.
The activity versus time profile from quantitative imaging is then integrated to arrive at
the time-integrated activity (TIA) which will be used in radiation dose calculation as
discussed in the following. Dosimetry for each treatment cycle is important as it will be
used to plan the subsequent treatment cycle of fractionated radionuclide therapy: whether
to give another cycle of the same activity, adjust the activity to be administered, or stop
treatment if the planned dose threshold is reached.187,188 Dosimetry is therefore used to
track cumulative radiation dose to correlate with treatment response and normal organ
toxicity.

2.2 Definition: Absorbed Dose
The absorbed dose, 𝐷 is defined as the energy, 𝑑𝐸 , deposited by ionizing radiation in the
target media of mass 𝑑𝑚 is given in Equation 2.1.
𝑫=

𝒅𝑬
𝒅𝒎

2.1

The standard international (SI) unit of radiation dose is gray (Gy), defined as 1 Joule of
energy absorbed per kilogram mass.189
Targeted radionuclide therapy absorbed dose calculations are used to assess the
associated deterministic effect (for cancer cure) and stochastic risks (for radiationinduced cancer) as well as the efficacy of treatment (tumor dose).190 Historically, the
approach published by the Medical Internal Radiation Dose (MIRD) Committee in the
1960s is used to calculate absorbed doses.183,191 For determining the absorbed dose to
target organs, the general MIRD equation is
̃ (𝒓𝑺 ) 𝑺(𝒓𝑻 ← 𝒓𝑺 )
𝑫(𝒓𝑻 ) = ∑ 𝑨
𝑺

2.2
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where 𝐴̃(𝑟𝑆 ) is the time-integrated activity of the radionuclide source and 𝑆(𝑟𝑇 ← 𝑟𝑆 )
also known as S-value is the dose deposited in the target 𝑟𝑇 per unit of cumulated (timeintegrated) activity in the source 𝑟𝑆 .
Time-integrated activity is the total number of decays of a radionuclide source integrated
over five times the effective half-life.192,193 The effective half-life (𝑇𝒆 ) is defined as
1
𝑇𝑝

1
𝑇𝑒

=

1

+ 𝑇 where 𝑇𝑝 refers to the physical half-life, and 𝑇𝑏 to the biological half-life. The
𝑏

time-integrated activity 𝐴̃(𝑟𝑆 ) is often normalized by the administered activity to form
the time-integrated activity coefficient.192 S-value is defined in Equation 2.3.
𝑺(𝒓𝑻 ← 𝒓𝑺 ) = ∑
𝒊

𝒏𝒊 𝑬𝒊 𝝋𝒊 (𝒓𝑻 ← 𝒓𝑺 )
𝒎𝑻

2.3

where 𝑚 𝑇 is the mass of the target, 𝑛𝑖 and 𝐸𝑖 are the frequency and energy of each
radiation type 𝑖, respectively, specifying the physical properties of the radionuclide, and
𝜑𝑖 (𝑟𝑇 ← 𝑟𝑆 ) is the absorbed fraction of energy emitted from the source that is deposited
in the target for each radiation type emitted by the radionuclide of relevance.

2.3 Dose Calculation Method
The absorbed dose in targeted radionuclide therapy can be calculated using three
methods: Organ S-value dosimetry, dose point kernel convolution and full Monte Carlo
(MC) simulation.194,195

2.3.1

Organ S-value Dosimetry

The organ S-value method uses the MIRD formalism to estimate the average absorbed
dose from internally distributed radionuclides in a volume of interest such as a whole
organ or the tumor volume.196 The absorbed dose of each organ is dependent on the
physical properties of the radionuclide, the injected activity, and the kinetics of
radioactivity uptake and clearance inside the tumor and normal tissue.196–198 The average
absorbed dose in the target organ, 𝐷(𝑟𝑇 ) is calculated using Equation 2.4.
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̃ (𝒐𝒓𝒈𝒂𝒏𝑺 ) 𝑺(𝒐𝒓𝒈𝒂𝒏𝑻 ← 𝒐𝒓𝒈𝒂𝒏𝑺 )
𝑫(𝒐𝒓𝒈𝒂𝒏𝑻 ) = ∑ 𝑨

2. 4

𝑺

where 𝐴̃(𝑜𝑟𝑔𝑎𝑛𝑆 ) is the average time-integrated (cumulative) activity of the source
organ, and 𝑆(𝑜𝑟𝑔𝑎𝑛 𝑇 ← 𝑜𝑟𝑔𝑎𝑛𝑆 ) is the average dose deposited in a target organ
(𝑜𝑟𝑔𝑎𝑛𝑇 ) per average cumulated activity in the source organ (𝑜𝑟𝑔𝑎𝑛𝑆 ). Several
dosimetry applications have been created using the MIRD formalism for dose calculation.
The most extensively used organ-level dose software package is Organ Level Internal
Dose Assessment/Exponential Modeling (OLINDA/EXM).199–201 OLINDA/EXM allows
inputs such as the organ time-integrated activity and organ-level S-values 𝑆(𝑜𝑟𝑔𝑎𝑛𝑇 ←
𝑜𝑟𝑔𝑎𝑛𝑆 ) to calculate the average absorbed dose for each organ. S-values is precalculated
by Monte Carlo simulation in standard phantoms representing the average
geometry/anatomy of male or female. In these simulations, activity is assumed to be
uniformly distributed in source organs, and the dose is assumed to be uniformly deposited
throughout each target organ which is also assumed to be uniform in its radiation
interaction properties including density.193,202
The main drawback of the organ S-value method used in OLINDA/EXM is that a patientspecific absorbed dose estimate is not available since the 𝑜𝑟𝑔𝑎𝑛𝑆 values are based on
standard phantoms rather than patient geometry/anatomy.193,203 Specifically, by assuming
uniform activity distributions, OLINDA/EXM can estimate dose in tumors in the form of
uniform density spheres of varied sizes based on the organ S-value. This approach does
not provide voxelized 3D dose distribution in tumors.204
Differences in mean absorbed doses estimated using OLINDA/EXM compared to doses
computed using full Monte Carlo simulations based on patient CT scans have been
reported as high as 31% for tumors and 97% for normal tissues in studies.205 Researchers
have extended the MIRD schema to calculate absorbed doses at the voxel level using
voxel S-values (which is the same as dose point kernel convolution, §2.3.2) since organlevel dosimetry has limitations as discussed above.
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2.3.2

Dose Point Kernel Convolution

Although MC simulation is the most accurate method for voxel-based absorbed dose
calculations at the present, it is time-consuming, computationally expensive, and
generally hard to implement.206,207 As a result, numerous groups have proposed fast,
voxel-based dosimetry methods based on dose point kernel (DPK) convolution or voxel S
value (VSV) superposition techniques, which have been shown to overcome the
limitations of the full MC method in clinical dosimetry.208,209
The dose-point kernel is the spatial distribution of absorbed dose around an isotropic
point source of radiation in a homogeneous infinite medium, typically water.210–212 Based
on the principle of reciprocity, the superposition of VSV is the same as DPK convolution,
therefore dose calculation using convolution (superposition) of DPK is the same as
superposition (convolution) with VSV.204
A schematic diagram of DPK formalism and voxel S-value formalism is shown in Figure
2.1. DPK formalism distributes center pixel (0) energy to neighboring pixel (1 −
8). With an activity distribution, a superposition of DPK is required to calculate dose
distribution. DPK(0 ⇾ K) where K = 1 to 8 is the fraction of center pixel energy
deposited in pixel K. Voxel S value formalism distributes energy from neighboring pixel
(1’ − 8’) to centre pixel (0’). S(0’ ⇾ K’) where K’ = 1′ to 8′ is the fraction of
neighboring pixel energy that is deposited in center pixel 0’. With an activity distribution,
a superposition of the voxel S value is required to calculate dose distribution.

Figure 2.1: (A) DPK formalism and (B) Voxel S value formalism in the distribution of
energy from radionuclide.
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Based on the patient-specific PET/SPECT images, the absorbed dose distribution is then
determined by convolving the time-integrated activity distribution with the DPK or VSV
calculated by MC simulation.204,213 The voxel dose 𝐷𝑣𝑜𝑥𝑒𝑙𝑗 (Gy) is given in Equation 2.5:
𝒏

̃ ⊗ 𝑫𝑷𝑲 = ∑ 𝑨
̃ 𝒗𝒐𝒙𝒆𝒍 × 𝑫𝑷𝑲(𝒗𝒐𝒙𝒆𝒍𝒊 → 𝒗𝒐𝒙𝒆𝒍𝒋 )
𝑫𝒗𝒐𝒙𝒆𝒍𝒋 = 𝑨
𝒊

2.5

𝒊=𝟎

where 𝐷𝑣𝑜𝑥𝑒𝑙𝑗 is the absorbed dose in 𝑗𝑡ℎ target voxel, 𝐴̃𝑣𝑜𝑥𝑒𝑙𝑖 is the time-integrated
activity in the 𝑖𝑡ℎ source voxel and 𝐷𝑃𝐾(𝑣𝑜𝑥𝑒𝑙𝑖 → 𝑣𝑜𝑥𝑒𝑙𝑗 ) is the DPK in the 𝑗𝑡ℎ voxel
per unit decay in the 𝑖𝑡ℎ voxel. The 𝐴̃𝑣𝑜𝑥𝑒𝑙𝑖 value in each voxel can be derived from the
PET or SPECT image (see §2.3.4).

2.3.3

Full Monte Carlo Simulation

The Monte Carlo (MC) simulation originated in Los Alamos in the 1940s when
physicists working on particle transport problems began solving them using something
which they termed the Monte Carlo method.214 The MC method is a computational
approach that uses random number sampling to perform numerical calculations of
ionizing radiation interactions (transport) with matter.

The

MC dose calculation

methods use general-purpose MC codes like Geant4, MCNP, EGSnrc, or EGS to model
voxelized dose distributions within tumor, as well as in normal healthy tissues. 215–219
To simulate radiation transport, MC codes leverage known physics of photon and particle
interactions with tissue media.220 MC simulations simulate ionizing radiation (photons
and charge particles) traveling through a patient geometry (often referred to as a
phantom) by using interaction cross-section data for different media (tissues).
The simulation procedure can be summarized as follows: A primary decay of ionizing
radiation, sampled at the source, travels a certain distance, determined by the probability
distribution based on the total interaction cross-section, to the site of a collision and
scatters into another energy and/or direction, based on the differential cross-sections. The
procedure is repeated until the ionizing radiation has been completely absorbed or has left
the geometry under consideration. Any secondary particles (such as knock-on electrons
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and bremsstrahlung photons) generated with significant kinetic energy are simulated as
well. The energy deposited at each interaction site over the paths travel by both the
primary and secondary radiation is tallied. In most MC codes, radiation (both primary
and secondary) transport is performed down to an energy cutoff threshold of 1 keV or
less. When the radiation reaches the cutoff energy threshold or is generated at or below
this threshold, radiation transport stops. The estimated remaining energy is deposited at
the stopping site in the phantom as low energy radiation below the cutoff threshold is
unlikely to escape from the scoring region due to its short range.
The dose distribution in the phantom is derived from the total tallied dose normalized by
all simulation histories or the total time-integrated activity over the entire phantom
(discussed in §2.3.3.1). The statistical uncertainty of the calculation depends on N, the
number of particle histories simulated and typically decreases with N-1/2.221 This may lead
to long calculation times depending on the desired precision and/or the complexity and
size of the geometry. The variance reduction technique is used to reduce the number of
histories required to reach the same low uncertainties thereby increasing simulation
efficiency.222
With SPECT or PET images providing quantitative information about the cumulated
activity distributions, MC simulation can be used to simulate ionizing radiation transport
in the body of a patient and calculate the resulting 3D dose distributions.210–212 The
simulation model can be set using patient-specific CT images, allowing the technique to
account for patient-specific source and target organ anatomies as well as tissue
inhomogeneities.193,223
Patient-specific dose estimate using full MC simulations is considered the potentially
most accurate technique to predict radiation dose from targeted radionuclide therapy
because full MC simulation accounts for heterogeneity in activity distribution in both the
tumor and critical healthy organs, patient-specific anatomy and tissue inhomogeneity in
density and composition (e.g. bone/calcifications vs soft tissue).208,224 However, despite
the availability of a wide range of MC codes, dosimetry treatment planning systems
based on such codes have yet to achieve widespread acceptability in clinical practice
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because MC dose calculation is computationally intensive and there is no convenient
reference standard to validate the dose obtained.225,226

2.3.3.1

Interpretation of Dose Distribution from Monte Carlo
Simulation

The dose distribution in a phantom using in Monte Carlo simulation method is given by
Equation 1.6
𝑀

𝑁

𝑆(𝑥𝑖 → 𝑥, 𝑦𝑗 → 𝑦, 𝑧𝑘 → 𝑧)
𝐸(𝑥, 𝑦, 𝑧)
𝐷(𝑥, 𝑦, 𝑧) =
= ∑ ∑ 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑀(𝑥, 𝑦, 𝑧)
𝑀(𝑥, 𝑦, 𝑧)

2.6

𝑘=1 𝑖,𝑗=1

where 𝐷(𝑥, 𝑦, 𝑧) is the dose (energy deposited, 𝐸(𝑥, 𝑦, 𝑧)) at voxel (𝑥, 𝑦, 𝑧) from decays
(𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )) at all (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ), 𝑆(𝑥𝑖 → 𝑥, 𝑦𝑗 → 𝑦, 𝑧𝑘 → 𝑧) is the energy deposited at
(𝑥, 𝑦, 𝑧) from a decay at (𝑥𝑖 , 𝑦𝑗, 𝑧𝑘 ), 𝑀(𝑥, 𝑦, 𝑧) is the voxel mass. 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
is related to the time activity, 𝑇𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡), at time 𝑡 as:
∞

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) = ∫ 𝑇𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝑑𝑡

2.7

0

where ∞ is the shorter of five biological or physical half-lives of the radionuclide at
voxel (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ).
Dividing Equation 2.6 by the total TIA over all (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ), we have:
𝐷(𝑥, 𝑦, 𝑧)
𝑁
∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑀

𝑁

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

𝑆(𝑥𝑖 → 𝑥, 𝑦𝑗 → 𝑦, 𝑧𝑘 → 𝑧)
=∑ ∑ 𝑀
𝑀(𝑥, 𝑦, 𝑧)
∑𝑘=1 ∑𝑁
𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑘=1 𝑖,𝑗=1

The probability of decay at (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) can be estimated as:

2.8
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𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) =

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑀
∑𝑘=1 ∑𝑁
𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

2.9

Rewriting Equation 2.8 in terms of 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) :
𝑀

𝐷(𝑥, 𝑦, 𝑧)
𝑁
∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

𝑁

= ∑ ∑ 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑘=1 𝑖,𝑗=1

𝑆(𝑥𝑖 → 𝑥, 𝑦𝑗 → 𝑦, 𝑧𝑘 → 𝑧)
𝑀(𝑥, 𝑦, 𝑧)

2.10

For Monte Carlo simulation with 𝑁𝐻 histories, Equation 2.10 is modified as:
𝐷(𝑥, 𝑦, 𝑧)
𝑁
∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑀

𝑁

𝑆(𝑥𝑖 → 𝑥, 𝑦𝑗 → 𝑦, 𝑧𝑘 → 𝑧)
1
=
∑ ∑ 𝑁𝐻 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑁𝐻
𝑀(𝑥, 𝑦, 𝑧)

2.11

𝑘=1 𝑖,𝑗,𝑘=1

𝑁
In Equation 2.11, ∑𝑀
𝑘=1 ∑𝑖,𝑗,𝑘=1 𝑁𝐻 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

(𝒙, 𝒚, 𝒛) for 𝑵𝑯 histories while

𝟏
𝑵𝑯

𝑆(𝑥𝑖 →𝑥,𝑦𝑗 →𝑦,𝑧𝑘 →𝑧)
𝑀(𝑥,𝑦,𝑧)

is the dose deposited in

𝑵
∑𝑴
𝒌=𝟏 ∑𝒊,𝒋=𝟏 𝑵𝑯 𝑷(𝒙𝒊 , 𝒚𝒋 , 𝒛𝒌 )𝑺(𝒙𝒊 → 𝒙, 𝒚𝒋 → 𝒚, 𝒛𝒌 →

𝒛) = 𝑴𝑪𝒏𝒐𝒓𝒎 (𝒙, 𝒚, 𝒛) is the dose per decay or the normalized dose from the Monte
Carlo simulation. If the simulation is correct, 𝑀𝐶𝑛𝑜𝑟𝑚 (𝑥, 𝑦, 𝑧) should be independent of
the number of histories, 𝑁𝐻 , used in the simulation. That is, mean 𝑀𝐶𝑛𝑜𝑟𝑚 (𝑥, 𝑦, 𝑧) should
have zero bias, or it is independent of 𝑁𝐻 but the standard deviation should increase with
decreasing 𝑁𝐻 .
Equation 2.11 also states that 𝑀𝐶𝑛𝑜𝑟𝑚 (𝑥, 𝑦, 𝑧) in Equation 2.12 is the dose at (𝑥, 𝑦, 𝑧)
divided by the total TIA. Thus, the voxel dose distribution, 𝐷(𝑥, 𝑦, 𝑧), is the normalized
dose distribution from the Monte Carlo simulation, 𝑀𝐶𝑛𝑜𝑟𝑚 (𝑥, 𝑦, 𝑧), multiplied by the
summed TIA over all voxels. The voxel dose distribution divided by the summed TIA
over all voxels is the normalized dose distribution from the Monte Carlo simulation.
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𝑀𝐶𝑛𝑜𝑟𝑚 (𝑥, 𝑦, 𝑧) =

𝐷(𝑥, 𝑦, 𝑧)
𝑁
∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

=

𝐸(𝑥, 𝑦, 𝑧)⁄𝑀(𝑥, 𝑦, 𝑧)
𝑁
∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

2.12

In summary, the 3D dose map produced by egs_mird is:
𝑁

1
∑ 𝑁𝐻 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )𝑆(𝑥𝑖 → 𝑥, 𝑦𝑗 → 𝑦, 𝑧𝑘 → 𝑧)
𝑁𝐻
𝑖,𝑗,𝑘=1

in units of Gy per decay. To convert to more convenient units of 𝜇𝐺𝑦(𝐺𝐵𝑞 ∙ 𝑠)−1, the
voxel values have to be scaled by 1015 . For DVH generated with egs_mird 3D dose after
it has been scaled by 1015 , the horizontal axis is in units of 𝜇𝐺𝑦(𝐺𝐵𝑞 ∙ 𝑠)−1.
The egs_mird dose calculation is based on the probability distribution, 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ). As
shown in Equation 2.8:

𝑃(𝑥𝑖 , 𝑦𝑖 , 𝑧𝑘 ) =

2.3.4

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )
𝑁
∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

Quantification of Time-Integrated Activity from PET/SPECT
Images

The activity of radioactive materials measures the number of radioactive decay that occur
per unit of time. According to the International System of Units (SI), the unit for activity
is the Becquerel (Bq), defined as one disintegration (decay) per second, and is measured
in reciprocal seconds (s-1). The older standard, the curie (Ci), is still in common usage
and 1 Ci = 3.7 × 1010 Bq.
The radiolabelled molecule (or radiopharmaceutical) is injected intravenously into a
patient's bloodstream to assess disease extent (diagnosis), TRT treatment planning and
dosimetry. For these purposes, especially dose calculation, the distribution of activity
concentrations (Bq/mL) in the tumor and organs and tissues of individual patients has to
be determined.227 In quantitative nuclear medicine, SPECT and PET are used to visualize
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the distribution of radiopharmaceuticals in a patient's body and to determine the absolute
activity concentration of the radiopharmaceutical.
where 𝐶𝑇 is the count rate (counts per unit time (cps)) in the phantom as measured by the
PET or SPECT scanner and 𝐴𝑐𝑇 is the actual activity concentration in the phantom. Both
count rate and activity concentration are corrected for radioactive decay at the same time
of measurement.

Figure 2.2: Time-integrated activity quantification workflow
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To determine the time-integrated activity following a radiopharmaceutical injection,
SPECT or PET images are acquired at different time intervals. Because PET and SPECT
images are affected by attenuation, scatter, and patient motion, they have to be corrected
for these effects first. The corrected image pixel values (count rate) are then converted
into activity concentration via the pre-determined calibration factor according to the
formula in Equation 2.14.228
𝑨𝒄𝒊 =

𝑪𝒊
𝑺

2.13

where 𝐶𝑖 and 𝐴𝑐𝑖 are the corrected image pixel value and activity concentration at 𝑖𝑡ℎ
pixel respectively and 𝑆 is the scanner calibration factor. The voxel volume, ∆𝑣, is used
to convert activity concentration into activity at the 𝑖𝑡ℎ pixel shown in Equation 2.13.
𝑨𝒊 = 𝑨𝒄𝒊 ∆𝒗

2.14

Since radiopharmaceuticals take time to decay or to be cleared from the tumor and
tissues, SPECT or PET studies are acquired at different times after injection. Since decay
and many clearance processes are exponential in nature, multiexponential functions are
widely used to fit time activity curve data derived from sequential PET and SPECT
images following radiopharmaceutical injection.
The cumulated (or time-integrated) activity (in units of Bq.s) is defined as the integral of
the activity over time. The time-integrated activity can be determined by fitting the
measured data to a summation of exponential terms or another mathematical function that
can be integrated analytically. In dynamic PET, B-splines have been proposed for
estimating activity using parametric estimation.229 This fitting method can also be applied
to SPECT imaging. For the spline method, the time-integrated activity was calculated
using Equation 2.16.
𝑻

∞

̃ 𝒔 = ∫ 𝑨(𝒕) 𝒅𝒕 + ∫ 𝑨𝒇 𝒆−ℷ𝒕 𝒅𝒕
𝑨
𝟎

𝑻

2.15
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where 𝐴̃𝑠 is the time-integrated activity, 𝐴(𝑡) is the spline fitted time-activity curve at
which imaging was terminated, 𝐴𝑓 is the activity of the organ at the end of the last PET
or SPECT scan, λ is the decay rate constant of the radionuclide and T is the time at which
sequential imaging was terminated.
Ahkvanallaf et al198, using a Siemens Biograph mCT hybrid PET/CT scanner, imaged
patients after intravenous injection of

18

F-FDG tracer. PET images of the patients were

acquired at 13-time points. The time-integrated activity was calculated by integrating
voxelwise time activity curves over 13-time points within the dynamic PET frames using
Equation 2.17:
𝟏𝟑

∞

̃ 𝒔 = ∑( 𝑨𝒊 + 𝑨𝒊+𝟏 ). ∆𝒕𝒊 + ∫ 𝑨𝒇 𝒆−ℷ𝒕 𝒅𝒕
𝑨
𝒊=𝟎

2.16

𝑻

where 𝐴̃𝑠 is the cumulated activity, 𝐴𝑖 is the activity obtained from the images pixel at the
𝑖𝑡ℎ time frame, 𝐴𝑓 is the activity concentration in the last time point of measurement, λ is
the decay rate constant of the radionuclide and T is the bladder voiding time.

2.4 Thesis Objectives and Outline
The objective of this thesis is two folds. Firstly, to validate an egs_mird (an in-house MC
simulation code) program and see if it agrees with itself and well-established MC codes.
Secondly, to develop a 3D voxel-level dose point kernel convolution method and
investigate whether it is accurate for patient-specific TRT dosimetry in prostate cancer.

2.4.1

Chapter 3: egs_mird MC code validation

To validate egs_mird, both internal and external consistency tests were performed. The
internal consistency test measures the agreement between various simulations computed
using egs_mird while the external consistency test assesses the correlation between the
same simulation but calculated using different MC codes. In the internal consistency
tests, egs_mird is used to calculate energy deposition in DPKs of different voxel sizes
and the results are compared with the theoretical calculation. While in the external
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consistency tests, the DPKs for different radionuclides generated by egs_mird are
compared against those obtained by different MC codes published in the literature.

2.4.2

Chapter 4: Three-dimensional Voxel-level Dose Point Kernel
Convolution Code

The validation of the 3D voxel-based DPK convolution code is presented. This chapter
introduces the 3D voxel-based DPK convolution code developed in my research and
investigates whether it is accurate in comparison to MC simulation for patient-specific
dosimetry in prostate cancer using the time-integrated activity (TIA) distribution from a
diagnostic dynamic PET [18F]DCFPyL or [18F]FCH study to approximate that of
[177Lu]PSMA-617 used in TRT.

2.4.3

Chapter 5: Conclusion and Future Direction

Chapter 5 contains the thesis summary, a discussion of how tissue density
inhomogeneities affect the DPK convolution result, and future directions. The future
direction will account for tissue inhomogeneities, estimate the biological effective dose
(BED) and the time-integrated activity.
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Chapter 3

3

egs_mird Validation

Monte Carlo (MC) codes such as GEANT4 and GATE have been used for targeted
radionuclide therapy dosimetry. However, their dose calculations are based on
assumptions about patient geometry (uses reference phantoms to model patient geometry)
and activity distribution.208,230–232 Thus, we developed egs_mird to calculate a patientspecific absorbed dose distribution in targeted radionuclide therapy using individual
patient CT for the definition of patient geometry and density distribution and PET or
SPECT scans for integrated time activity distribution.233 This chapter introduces
egs_mird MC code and validates it using both internal and external consistency test.

3.1 egs_mird Monte Carlo Code
egs_mird is an egs++ application developed from the EGSnrc MC code that scores dose
in a 3D array and outputs the result in an EGSnrc .3ddose file. EGSnrc MC code toolkit
is used to simulate the transport of ionizing radiation through matter. With the egs_mird
MC code, ionizing radiation emitted by radionuclides (such as photons, electrons, and
positrons) is simulated in a patient geometry defined by CT for density and tissue type
(media). egs_mird takes certain input files similar to EGSnrc application for its
simulation. egs_mird input file is conveniently saved as Filename.egsinp.

3.1.1

egs_mird Monte Carlo Code

This section offers a brief description of the various components of the input files that
egs_mird requires. egs_mird input files are identical to that of other egs++
applications.234 In all cases, the input blocks start and end with :start and :stop delimiter
statements. For example:
:start some input:
my_inputs (one or more lines)
:stop some input:
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The egs_mird input blocks that are commonly required are run control, media definition,
phantom geometries, source definition, scoring options, variance reduction, and MC
transport parameters.

3.1.1.1

Run Control

The :start run mode: block of the input file specifies how many histories to run (ncase)
and additionally, nbatch, nchunk if needed. EGSnrc applications divide simulations into
nchunk 'chunks,' which are beneficial during parallel runs because they allow for a better
balance of computation time on each computer, even if their speeds are considerably
different. By default, nchunk=1 for simple runs with no parallelization, and nchunk=10
for parallel runs. The job is broken into ncase/(npar*nchunk) 'chunks' of history for
parallel runs, where ncase is the total number of histories to be done in parallel on npar
machines. When jobs from different 'chunk' are completed, they are combined. Thus,
faster machines can run more 'chunks' in this manner. The input block run control is
specified as:
:start run control:
ncase
= 100000000
nbatch
= 1
:stop run control:

3.1.1.2

Media Definition

It requires a :start media definition: input block which inputs the values of AE, UE, AP
and UP. The lower and upper energy thresholds of charged particles are denoted by AE
and UE, respectively. AP and UP are used to represent the lower and upper energy
thresholds of photons, respectively. Another input in the media definition is materials
defined in the material.dat file. The material.dat file contains tissue media composition
with their densities. The media definition is defined as, for instance:
:start media definition:
AE = 0.512
UE = 2.012
AP = 0.001
UP = 1.500
material data file = material.dat
:stop media definition:
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The material.dat file is specified as:
medium = Prostate
rho = 1.040
elements = H, C, N, O, NA, P, S, CL
mass fractions = 0.105, 0.089, 0.025, 0.774, 0.002, 0.001, 0.002,
0.002
bremsstrahlung correction = NRC

3.1.1.3

Geometry Definition

This block tells egs_mird which geometry (phantom) to score dose in. The phantom
geometry in 3D can be user-defined or patient-specific geometry derived from the CT
images. Patient-specific CT densities are stored in egsphant file. The :start geometry
definition: input block takes input values from information contained in the material.dat
file (defining the tissue media and densities) specified in the media definition block. For
example, a user-defined 3D geometry is defined as:
:start geometry definition:
:start geometry:
library = egs_ndgeometry
type
= EGS_XYZGeometry
name
= phantom
x-planes = -10 -9 -7 -5 -3 -1 1 3 5 7 9 10
y-planes = -10 -9 -7 -5 -3 -1 1 3 5 7 9 10
z-planes = -10 -9 -7 -5 -3 -1 1 3 5 7 9 10
:start media input:
media = Prostate
:stop media input:
:stop geometry:
simulation geometry = phantom
:stop geometry definition:
Patient-specific geometry is defined as:
:start geometry definition:
:start geometry:
library
type
name
egsphant file
density file
:stop geometry:
simulation geometry = phantom
:stop geometry definition:

=
=
=
=
=

egs_glib
egsphant
phantom
FileName.egsphant
material.dat
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3.1.1.4

Source Definition

The :start source definition: input block specifies the required information about the
radioactive

sources

used

for

TRT.

egs_mird

uses

egs_internal_source

and

egs_radionuclide_source for its source definition. egs_internal_source takes two inputs: a
rectilinear patient geometry (i.e., a patient is defined as a 3D grid of voxels with the
appropriate media and densities) and a list of voxel regions with corresponding timeintegrated activity (TIA). The list of regions and weight is created into a table that can be
sampled at O(1) efficiency using the alias technique already provided in EGSnrc as the
class EGS AliasTable: (i.e., EGS AliasTable samples at the same rate regardless of table
size). To determine where to generate the particle, two random numbers are used.
Consequently, if a user has a heterogeneous TIA distribution over a patient geometry,
they can utilize it in the patient simulation. The egs_radionuclide_source is an egs++
source class that can simulate the decay (decay chain) of a variety of radionuclides used
in TRT (e.g.,

177

Lu, 90Y, 131I, 223Ra, and

225

Ac).233 Because ESGnrc is unable to simulate

alpha transport, all alpha particles generated in decay are considered to deposit their
energy locally.
Additionally, egs_mird also allows simulation with monoenergetic ionizing radiation
sources. To implement this, within the :start source definition: input block there is a
nested input block called :start source: which specifies the charge such as 0, -1, and 1 for
photons, electrons and positrons respectively. The energy spectrum of the source must be
specified in a :start spectrum: nested block. This spectral input is monoenergetic, with the
energy set (in MeV).”

3.1.1.5

Scoring Options

The :start scoring options: input block specifies the geometry to score dose, the output
filetype and filename. For example, the input block of the scoring option is defined as:
:start scoring options:
type
= 3ddose
file name
= fileName.3ddose
scoring geometry = phantom
:stop scoring options:
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3.1.1.6

Variance Reduction

The :start variance reduction: is used to turn on variance reduction techniques. The
variance reduction is an optional input block in egs_mird that allows the user to enable
tracklength scoring and choose a data file containing the energy absorption coefficient
(µen) data used in the calculation. The :start variance reduction: block id defined as:
:start variance reduction:
score tracklength dose
muen file
:stop variance reduction:

= yes
= XCOM_muen_1500keV.muendat

A photon tracklength estimator is a variance reduction technique based on the premise
that all electrons deposit their energy locally at low photon energies, allowing the dose to
be approximated as collision kerma.233,235 It requires setting the electron transport cutoff
to the maximum energy, implying that no electrons are transferred during the simulation
and instead deposit their energy locally when formed. A photon traveling through a
volume is counted as a dose deposition event when employing tracklength scoring. Using
the total tracklength across the volume (t), the appropriate mass-energy absorption
coefficient (µen/ρ) and the energy of the travelling photon (E), the dose deposited in this
event (De) to the scoring volume (V) may be calculated using Equation 3.1.

𝑫𝒆 =

𝒕∙𝑬∙

𝝁𝒆𝒏
⁄𝝆
𝑽

3.1

A large increase in simulation efficiency can be realized by scoring dose along a photon's
track rather than in individual interaction events; even though a single photon history
using tracklength scoring takes longer to compute, the total number of histories required
to attain low uncertainties can be greatly reduced. The egs_mird application and
egs_internal_source are available at the https://github.com/Robarts-Lee-Lab/egs_mird
website and egs_radionuclide_source is available as a pull request on the main EGSnrc
github page at https://github.com/nrc-cnrc/EGSnrc.
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3.2 Methods
To validate egs_mird, both internal and external consistency tests were performed. The
internal consistency test measures the agreement between various simulations computed
using egs_mird while the external consistency test assesses the correlation between the
same simulation but calculated using different MC codes. In the internal consistency test,
egs_mird was used to calculate dose point kernels (DPKs) at different voxel sizes and the
energy deposition is compared with the energy of the radionuclide source. While in the
external consistency test, the DPKs generated by egs_mird are compared against DPKs
obtained by different MC codes published in the literature.

3.2.1

Internal Consistency Test

The egs_mird MC code was used to generate the DPKs of

177

Lu and two ‘fake’

radionuclides one emits a monoenergetic photon of energy 120 keV and 500 keV.
Another emits monoenergetic electrons of energy 500 keV at a voxel resolution of 1x1x1
mm3 and 2x2x2 mm3. Energy deposition in different volumes was calculated by summing
the corresponding DPK values and then scaling the summation by the voxel mass. The
internal consistency tests consisted of testing for energy conservation in three different
ways. First, the energy deposited by 177Lu in volumes of different sizes as evaluated from
the DPK generated by egs_mird using different voxel resolutions was compared; second,
the total energy deposited by

177

Lu was evaluated as the summation of all (non-zero)

DPK values scaled by the voxel mass was compared with the total energy emitted from a
single decay of the radionuclide which has a spectrum of energy emissions, third, energy
conservation is also tested for the two ‘fake’ radionuclides with monoenergetic photon
and electron emission respectively.
For the first energy conservation test, DPK simulation was performed using

177

Lu as the

radionuclide source. A schematic diagram of the simulation phantom is shown in Figure
3.1. The simulation phantom 20 x 20 x 20 cm3 in size consisted of prostate media with a
density of 1.03 g/cm3. with egs_mird at a voxel resolution of 1x1x1 mm3 and 2x2x2
mm3.
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Figure 3.1: Schematic diagram of DPK phantom. The source,

177

Lu radionuclide source

was positioned at the center voxel. The DPK phantom was filled with prostate media with
a density of 1.03 g/cm3.
For the second energy conservation test, the total energy on average emitted from a 177Lu
decay cannot be accurately calculated theoretically from its decay due to characteristic Xray emission and Auger emission cascades (Kα, Kβ, KLX, KXY) are cited in
probabilities and have a range of energies, Instead, egs_mird was used to calculate the
177

Lu DPK with all transport processes turned off and the energy deposited at the center

voxel was taken as the (average) energy emitted by a single decay of
The

177

Lu

decay

scheme

is

177

Lu radionuclide.

available

at

http://www.nucleide.org/DDEPWG/DDEPdata.htm.
For the final test of energy conservation, DPKs of 500 keV monoenergetic electron and
photon of energy 500 keV and 120 keV in a phantom of either 65x65x65 cm3 or
100x100x100 cm3.
All DPK simulations in the internal consistency tests used the default EGSnrc transport
parameters: Compton scattering, Rayleigh scattering, and electron impact ionization
switched on, pair angular sampling was set to off, and bremsstrahlung cross sections set
to ‘NIST’. DPK simulations were performed with 3 x 109 decays (histories) without
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employing variance reduction techniques. Electrons and photons were transported with a
cutoff kinetic energy of 1 keV.

3.2.2

External Consistency Test

A 3D DPK for the three radionuclide sources (90Y,

131

I and

177

Lu) were calculated using

the egs_mird MC code and compared to those calculated with general-purpose MC
codes: DOSXZnrc, EGS4, MCNP4C, GEANT4 and vxlPen (application developed using
PENELOPE) found in literature.213,236
The transport of electrons and photons emitted by radionuclide sources are simulated in a
homogenous medium of soft tissue according to the Cristy and Eckermann elemental
composition shown in Table 3.1.237
Table 3.1: Cristy and Eckermann's elemental composition.237
Element
H
C
N
O

Percentage by weight
10.454
22.663
2.490
63.525

Na

0.112

Mg

0.013

Si

0.030

P

0.134

S
Cl
K
Ca
Fe
Zn
Rb
Zr
Pb
Density

0.204
0.133
0.208
0.024
0.005
0.003
0.001
0.001
0.001
1.400 g/cm3

The deposited energy is scored in cubic voxels with a voxel resolution of 3 mm in
phantom size of 16.5 x 16.5 x 16.5 cm3 for

90

Y and

131

I and in cubic voxels of 4 mm
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resolution in phantom size of 43.6 x 43.6 x 43.6 cm3 for

177

Lu source. The DPK

simulations were implemented using egs_internal_source and egs_radionuclide_source.
The radionuclide source was placed at the center voxel of each phantom in 3D Cartesian
geometry. The energy and frequency of emissions of the radionuclide sources were
obtained

from

the

Brookhaven

National

Laboratory

database

available

at

http://www.nucleide.org/DDEPWG/DDEPdata.htm.
All simulations used the default EGSnrc transport parameters: Compton scattering,
Rayleigh scattering, and electron impact ionization switched on, pair angular sampling
was set to off, and bremsstrahlung cross sections set to ‘NIST’. DPK simulations were
performed with 2.5 x 107 decays (histories) without employing variance reduction
techniques. Electrons and photons were transported with a cutoff kinetic energy of 1 keV.
The egs_mird 131I and 90Y DPK results were compared to DOSXZnrc, EGS4, MCNP4C,
GEANT4 found in a literature whereas

177

Lu DPK result was compared to vxlPen found

in another literature.213,236 The absorbed dose scored in each voxel was normalized in
units of mGy.MBq-1.s-1.

3.3 Results
Here results of external and internal consistency tests of egs_mird are presented. In
general, for the internal consistency tests, egs_mird passed the three energy conservation
tests; for the external consistency tests, egs_mird DPKs for 90Y, 131I and 177Lu agree with
those generated by other MC software packages.

3.3.1

Internal Consistency Test

Figure 3.2 shows the DPK of

177

Lu radionuclide generated by egs_mird for 1 mm and 2

mm voxel resolution. In Table 3.2, the energy deposition profile in volumes of 1 – 125
cm3 calculated from 1 mm voxel resolution DPK overlaps with that calculated from 2
mm voxel resolution DPK, showing good agreement or energy is conserved independent
of voxel resolution used in the generation of DPK.
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Figure 3.2:

177

Lu DPKs generated with egs_mird for 1 mm (in blue) and 2 mm (in red)

voxel resolution.
As shown in Table 3.3, the total energy deposition from a

177

Lu radionuclide source

estimated from 1 mm and 2 mm voxel resolution DPK shown in Figure 3.2 was
essentially identical to that obtained from a simulation with no radiation transport so that
all energy is deposited at the center voxel where the source was situated.
Table 3.2: Energy deposition profile of 177Lu in volumes of different sizes as estimated
from DPK of 1 mm and 2 mm voxel resolution.
Volume (cm3)
1
8
27
64
125

1 mm
Energy (J/decay)
2.52×10-14
2.53×10-14
2.56×10-14
2.60×10-14
2.63×10-14

2 mm
Energy (J/decay)
2.52×10-14
2.53×10-14
2.56×10-14
2.60×10-14
2.63×10-14
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Table 3.3: egs_mird Monte Carlo simulation using 1 mm and 2 mm voxel resolution of
total energy deposition from a

177

Lu radionuclide source. For comparison, energy

deposited for a simulation with no transport is also included.
egs_mird DPK simulation

Energy (J/decay)

1 mm voxel

2.7057×10-14

2 mm voxel

2.7064×10-14

No transport

3.0202×10-14

Simulations of total energy deposition from monoenergetic 120 keV and 500 keV
photons and 500 keV monoenergetic electrons with voxel dimensions of 0.976 x 0.976 x
3.51 mm3 in two different phantom sizes and with and without radiation transport are
summarized in Table 3.4. In each case, the percentage difference of total deposited
energy in the phantom relative to the reference energy of either the monoenergetic
electron or photon was calculated and listed in Table 3.4.
Table 3.4: Simulations of total energy deposition of monoenergetic 120 keV and 500
keV photon and monoenergetic 500 keV electron in (65 cm)3 and (100 cm)3 phantom
sizes.
Transport simulated

Total energy deposited (keV)

Energy diff (%)

Monoenergetic 500 keV photon in a 65x65x65 cm3 phantom
Photon transport
No photon transport

438.6
500

-12.3
0

Monoenergetic 500 keV electron in a 65x65x65 cm3 phantom
Electron transport
No electron transport

500
500

0
0

Monoenergetic 120 keV photon in a 65x65x65 cm3 phantom
Photon transport
114.9
-4.2
No photon transport
120.0
0
3
Monoenergetic 120 keV photon in a 100x100x100 cm phantom
Photon transport
119.5
-0.4
No photon transport
120.0
0
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3.3.2

External Consistency Test

Soft tissue DPKs for

90

Y,

131

I, and

177

Lu was estimated with egs_mird. Comparisons of

egs_mird DPKs with those from literature in Figure 3.3 to Figure 3.5 show good
agreement. The percentage difference (PD) of DPK values at the same distance from the
source was determined for each DPK profile using Equation 3.2.
𝑷𝑫(𝒊) =

𝑫𝒂(𝒊) − 𝑫𝒃(𝒊)
,
𝑫𝒂(𝒊)

𝒊 = 𝟎, ⋯ , 𝒏

3.2

where 𝐷𝑎 is the reference EGS4 DPK value, 𝐷𝑏 is the DPK value from other MC codes
and 𝑖 is the source-target voxel distance. 𝑖 = 0 corresponds to the center voxel and 𝑖 =
1, … 𝑛 corresponds to the distance away from the source (center). For

90

Y in Figure 3.3,

egs_mird had a 4% dose difference, DOSXYZnrc 11%, MCNP4C and GEANT4 2% for
the center voxel. At distance >6 mm, consistent differences in dose are observed for a
mean dose difference of 52% for egs_mird, 50% for MCNP4C, 56% for DOSXYZnrc,
and 47% GEANT4. The same comparison is reported for 131I in Figure 3.4. At the center
voxel, the difference reaches -3% for egs_mird, 10% for DOSXYZnrc, 4% for MCNP4C,
and 4% for GEANT4. At larger distances greater than 4 mm, differences are scattered
between -4% and 19% for egs_mird, 0% and 24% for DOSXYZnrc, -11% and 12% for
MCNP4C, and -11% and 12% for GEANT4.
Figure 3.5 shows the soft tissue DPK of

177

Lu calculated with egs_mird and vxlPen

profiles. In this case, the percentage dose difference comparison was carried out using
vxlPen as the reference. Results show good agreement at source distance greater than 4
mm with less than 0.004% dose deviation, except for the center voxel where it is 9.96%,
shown in Figure 3.5.
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Figure 3.3: Comparison of 90Y DPKs generated using egs_mird (black circle) to other
DPKs from the literature.

Figure 3.4: Comparison of 131I DPKs generated using egs_mird (black circle) to other
DPKs from the literature.
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Figure 3.5: Comparison of

177

Lu DPKs generated using egs_mird (black circle) to other

DPKs from the literature. A magnified scale of the DPK profile at the center voxel is
shown.

3.4 Discussion
The validity of egs_mird Monte Carlo code for targeted radionuclide therapy dosimetry
was investigated by checking the internal consistency of egs_mird results with respect to
energy conservation at different phantom voxel resolutions. Figure 3.2 shows that the
177

Lu DPK expressed in voxel number distance from the source voxel at 1 mm voxel

resolution is always higher than 2 mm voxel resolution. As dose is the quotient of the
energy deposited in a target voxel and the mass of the voxel. Thus, the discrepancies in
the DPKs shown in Figure 3.2 can be explained by the difference in voxel mass. The
egs_mird Monte Carlo simulation of total energy deposition by 177Lu derived from 1 mm
and 2 mm resolution DPK were in good agreement. Furthermore, the energy deposited
was in agreement with that from a simulation with no radiation transport. Monoenergetic
photons and electrons were used to further investigate the energy deposition in the DPK
volume to further validate the egs_mird Monte Carlo simulation code according to energy
conservation. The 120 keV monoenergetic photons simulation with radiation transport for
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both 65 cm x 65 cm x 65 cm and a 100 cm x 100 cm x 100 cm DPK volume showed a
significant decrease in energy deposition in the DPK volume, 12.27% and 4.22%
respectively with respect to the energy of the monoenergetic photon due to energy escape
from the phantom. As expected, since the escape of secondary radiation was less, the
decrease in energy deposition was less in the larger phantom. Electron interaction is
vastly different from photons. The energy deposition in the DPK volume for electron
simulation showed good agreement with the energy of the monoenergetic electron with
and without particle transport because a 500 keV electron travels only 1.78 mm in soft
tissues before it is completely stopped. The electron range in soft tissue was calculated
using

the

ESTAR

program

available

at

https://physics.nist.gov/PhysRefData/Star/Text/ESTAR.html.
In the external consistency tests, DPK for

90

Y,

131

I, and

177

Lu calculated by egs_mird

were in good agreement with those from other MC codes in the literature. All the DPKs
have a similar profile as shown in Figure 3.3 to Figure 3.5. At the center voxel where the
source was, the absorbed dose was very high compared to the surrounding voxels due to
energy deposition by electrons within a

few millimeters of the source. At larger

distances, the beta (electron) contribution became negligible relative to the
bremsstrahlung contribution.
As shown in Figure 3.3, the

90

Y DPK calculated by EGS4 diverges from egs_mird and

other MC codes from the literature. The algorithms for electron and photon transport and
multiple scattering events and cross-section libraries used in EGS4 code could be
different from egs_mird and other MC codes.236,238–241 Similarly for

131

I, in Figure 3.4,

egs_mird was in good agreement with the literature. At distances further away from the
source voxel, slight differences were noticed, from poor statistics due to the high-energy
spectrum of 131I.
Figure 3.5 shows that the

177

Lu DPK calculated by egs_mird agreed well with vxlPen

except at the source pixel where egs_mird was 9.96% higher than vxlPen. The source of
the difference was due to the difference in the

177

Lu emission spectrum used in the

simulation. In the vxlPen simulation, only primary emissions of

177

Lu were utilized,
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while excluding electron capture and Auger electrons. The egs_mird DPK simulation
included electron capture and Auger electrons which contributed a more absorbed dose at
the source voxel. Table 3.5 shows vxlPen excluded electron capture and Auger electron
contributed an additional 0.033 mGy/(MBq.s) at the source voxel. This missing dose
from vxlPen was close to the source voxel difference between egs_mird and vxlPen DPK
0.031 mGy/(MBq.s) (see inset in Figure 3.5). This result shows that the decay spectrum is
one of the critical factors that significantly affect the accuracy of dose calculation with
MC simulation. The dose in Gy/decay is converted to mGy/(MBq.s) by scaling Gy/decay
with 109. One decay is equivalent to one becquerel second (Bq.s).
Table 3.5: Theoretical calculation to estimate the absorbed dose from electron capture
and Auger electron not considered in vxlPen MC simulation of the decay of

177

Lu

radionuclide source.
Energy Frequency
(keV)
(%)
Auger-L e7.720
8.750
ce-K e6.291
0.123
Auger-K e- 53.647
0.283
ce-K e47.599
5.070
ce-L e101.678
6.840
ce-M e110.348
1.710
ce-K e143.015
0.570
ce-L e197.094
0.098
Emission

≈Range
(mm)
0.011
0.011
0.197
0.197
0.665
0.665
1.322
2.118

E. Dep
(J/decay)
1.08E-16
1.24E-18
2.43E-17
3.87E-16
1.11E-15
3.02E-16
1.31E-16
3.09E-17

Dose
(Gy/decay)
1.69E-12
1.94E-14
3.80E-13
6.04E-12
1.74E-11
4.72E-12
2.04E-12
4.84E-13
Total

Dose
(mGy/MBq.s)
1.69E-3
1.94E-5
3.80E-4
6.04E-3
1.74E-2
4.72E-3
2.04E-3
4.84E-4
3.28E-2

3.5 Conclusion
This work has validated egs_mird MC code which can be used to calculate a patientspecific dose distribution from TRT. Validation was completed using internal and
external consistency tests. Internal consistency tests were based on testing that energy
was conserved between

177

Lu DPK with and without transport as well as between

monoenergetic photon and electron DPK and the assumed energy also with and without
transport. The external consistency validation of egs_mird compared DPK for
and

177

90

Y,

131

I,

Lu calculated using egs_mird with those using other Monte Carlo codes such as

DOSXYZnrc, vxlPen, EGS4, MCNP4C, and GEANT4 cited in the literature.
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Chapter 4

4

Three-Dimensional Voxel-Level Dose Point Convolution
Code

4.1 Motivation
Targeted radionuclide therapy (TRT) requires an accurate calculation of the energy
deposited by a radionuclide per unit mass (dose) in patients to achieve optimal patient
outcomes.208,224 Visualizing patient-specific absorbed dose distributions in threedimensions (3D) is of high clinical value to avoid low-dose regions which might lead to
potential lesion recurrence and high-dose regions which could cause necrosis in normal
tissues. Moreover, normal organs might have sub-compartments that have different
tolerances to radiation, thus non-uniform dose distributions could result in different levels
of toxicity.208,224 Due to these reasons, patient-specific targeted radionuclide therapy
dosimetry is important for treatment planning to achieve an adequate dose to a tumor
without serious normal tissue toxicity and for establishing radiation dose-response of
biological tissues to guide clinical trials. A prerequisite to patient-specific 3D absorbed
dose calculation is the time-integrated activity (TIA) distribution of the administered
radionuclide over the residence time in the patient. The measurement of patient-specific
TIA by quantitative SPECT (e.g., 177Lu) or PET (e.g., 18F) is discussed in §2.3.4.208
With the patient-specific TIA known, the absorbed dose distribution in TRT can be
calculated using organ S-value, voxel S-value superposition (dose point kernel
convolution), or the Monte Carlo method as discussed in Chapter 2. Monte Carlo
simulation is the most accurate method for calculating voxel-based patient-specific
absorbed dose distributions at present, but it is time-consuming, computationally
expensive, and generally hard to implement. Besides overcoming the challenges of the
organ S-value dose calculation method as discussed in §2.3.1, DPK convolution, like MC
simulation, is a fast, voxel-based dosimetry method. This chapter introduces a 3D voxelbased DPK convolution (3DDC) code developed in my research and investigates whether
it is accurate and faster in comparison to MC simulation for patient-specific dosimetry in
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prostate cancer using the TIA distribution from a diagnostic dynamic PET [18F]DCFPyL
study to approximate that of [177Lu]PSMA-617 used in TRT.

4.2 Methods
4.2.1

Dynamic PET and CT Study

Registered CT and PET scan from a prospective clinical trial (NCT04009174) on men
with untreated biopsy-proven localized prostate cancer were used to obtain both the
patient-specific anatomy and TIA distribution. The institutional Research Ethics Board
approved the clinical trial protocol (NCT04009174). All participants provided written
informed consent before the investigation. A CT scan of the pelvis covering the entire
prostate gland was first obtained, followed by a dynamic [18F]DCFPyL PET scan where a
sequence of images of the same pelvic region as the CT scan was recorded over 22
minutes starting at the same time of injection of the radiotracer in an antecubital vein
with varied image durations of 10 seconds (10 image sets), 20 seconds (5 image sets), 40
second (4 image sets), 60 seconds (4 image sets), and 180 seconds (4 image sets). The
patient remained stationary on the patient's couch between the two imaging sessions. In
addition, to help localize the low resolution [18F]DCFPyL uptake in the patient’s
anatomy, the CT scans were also used for attenuation correction of PET activity, as well
as to determine the density and composition of tissue for MC simulations.
The CT and PET images had a thickness of 3.75 mm and 3.27 mm, respectively.
However, the CT voxel size was 0.98 x 0.98 x 3.75 mm3 while the PET voxel size was
3.90 x 3.90 x 3.27 mm3. The MIM Maestro (MIM Software Inc., OH, 195 USA) autocontouring software was used to contour the different organs/tissues – prostate, bladder,
rectum, and femurs – from the CT scans and the contours saved in a CT structure file.
The TIA distribution was derived from the dynamic PET images by integrating the timeactivity curves of each voxel by trapezoidal rule over the same duration of the PET
acquisition (i.e. 22 min).
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4.2.2

Conversion of PET and CT Data for DPK Convolution and
Monte Carlo Simulation

The patient PET and CT data were converted into an EGSnrc format geometry (egsphant
file) and an activity file that comprises a list of time-integrated activity for each voxel
using

in-house

conversion

tools

(available

at

https://github.com/Robarts-

LeeLab/DICOM). The patient geometry was determined by converting the HUs in 47 CT
slices to density using a HU versus density curve appropriate for the CT scanner. After
that, densities are used to assign media types (e.g., prostate, muscle, bone etc.) to various
regions. Media was assigned using an assignment scheme, which had previously been
employed with EGSnrc egsphant in brachytherapy242,243 and used the density thresholds
for all media as shown in Table 4.1. The media P50C50 was a media assigned to hybrid
prostate/calcification voxels that were assumed to be approximately 50% calcification (by
mass), to create a middle ground for voxels that are only partially calcified.
The voxel in each dynamic PET image was the average activity concentration over the
image acquisition interval, therefore the voxel TIA in units of Bq was calculated as the
sum of all dynamic images and then scaled by voxel volume which is 3.90 x 3.90 x 3.27
mm3 or 0.050 mL. The 3D TIA array was 128 x 128 (the same size as the PET images)
whereas the egsphant array from the patient CT images was 512 x 512. The TIA of each
egsphant voxel was linearly interpolated from the 3D TIA array. Any egsphant voxel
where the density was less than 0.75 g/cm3 was assumed to be air, and the corresponding
TIA was set to zero. As calcifications were shown to significantly influence dose results
in brachytherapy.242,243, two TIA arrays were generated for patients with calcifications in
the prostate to investigate their potential effect on the voxel-based dose distribution. One
with no further restrictions other than the air voxel TIA was set to zero and the other with
the TIA in calcification set to zero which was equivalent to halving the TIA in the hybrid
prostate/calcification voxels assuming their composition was 50:50.
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Table 4.1: The media assignment scheme used to assign the media described in Table 4.2 to different structures defined for the patient CT.
Structure
Patient
(everywhere)
Prostate

Rectum
Bladder
Femur

Density (g/cm3)
Lower
Upper
Air
0
0.75
Male Soft Tissue 0.75
1.14
Cortical Bone
1.14
∞
Prostate
0
1.14
P50C50
1.14
1.27
Calcification
1.27
∞
Rectum
0
∞
Bladder (full)
0
∞
Male Soft Tissue 0
1.14
Cortical Bone
1.14
∞
Medium

Table 4.2: The density and atomic composition of all elements used in this work with their accompanying source in the literature. DPK Tissue also
includes trace amounts of Mg, Si, Fe, Zn, Rb, Zr, and Pb not listed on the table.
Medium
Male Soft Tissue
Cortical Bone
Prostate
Calcification
Prostate/Calcification
Rectum
Bladder (full)
Marrow Yellow
Marrow Yellow-Red
Marrow Red
Air
Water

Density
(g/cm3)
1.030
1.920
1.040
3.060
1.552
0.750
1.030
0.980
1.000
1.030
0.001
0.998

H
10.500
3.400
10.500
0.300
5.400
6.300
10.800
11.800
11.000
10.600
0.070
11.110

C
25.600
15.500
8.900
1.600
5.250
12.100
3.500
64.600
53.100
41.700
0.010

N
2.700
4.200
2.500
0.500
1.500
2.200
1.500
0.700
2.100
3.400
75.030

Atomic Mass Fractions
O
Na
P
S
60.200 0.100 0.200 0.300
43.500 0.100 0.200 0.300
77.400 0.200 0.100 0.200
40.700 0.000 18.700 0.000
59.050 0.100 9.400 0.100
78.800 0.010 0.100 0.000
83.000 0.300 0.100 0.100
23.200
33.600
0.100
44.200
0.100
23.610
89.990

Source Paper
Cl
0.200
0.200
0.200
0.000
0.000
0.100
0.500

K
0.200
0.200
0.000
0.000
0.100
0.100
0.200

Ca

Ar

0.000
38.200
19.100
0.000
0.000

1.270

ICRU4611244
ICRU46244
ICRU46244
ICRU46 (for breast)244
50/50 hybrid medium
ICRU46244
ICRU46244
Schneider et al245
Schneider et al245
Schneider et al245
Rivard et al246
Rivard et al246
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4.2.3

Absorbed Dose Calculation Comparison between Analytical
Calculation, DPK Convolution and Monte Carlo Simulation

In order to validate the 3D dose convolution code, MC simulations with and without
(where the absorbed dose is deposited only at the center voxel) radiation transport were
used to calculate the DPK of a radionuclide source that emits a 500 keV monoenergetic
electron. The choice of this particular ‘fake’ radionuclide for the validation is that the
absorbed dose distribution corresponding to a uniform TIA of 1.0 Bq.s can be easily
calculated analytically. The analytically calculated dose distribution was then used as the
reference for comparison with those calculated by DPK convolution and MC simulation.
The 3D DPK simulation phantom 65 x 65 x 64 cm3 in size at a voxel resolution of 0.0976
cm x 0.0976 cm x 0.351 cm was filled with a uniform prostate media at a uniform density
of 1.03 g/cm3 and a TIA of 1.0 Bq.s per voxel. The total number of voxels in the phantom
was 513 x 513 x 47 = 12,368,943 and the total TIA in the phantom was numerically the
same since the TIA per voxel was 1.0 Bq.s. The 3D dose convolution code was used to
calculate (numerically) the absorbed dose by convolving the 3D DPK, 𝐷𝑃𝐾(𝒓) with the
time-integrated activity, 𝑇𝐼𝐴(𝒓). In principle, the absorbed dose, 𝐷(𝒓) can be calculated
analytically using Equation 4.1.
𝑫(𝒓) = 𝑫𝑷𝑲(𝒓)⨂𝑻𝑰𝑨(𝒓)

4.1

where ⨂ is the convolution operator. Expanding Equation 4.1 as a 3D convolution
integral yields Equation 4.2.
∞

𝑫(𝒓) = ∫ 𝑫𝑷𝑲(𝒔)𝑻𝑰𝑨(𝒓 − 𝒔)𝒅𝒔

4.2

𝟎

where 𝒓 and 𝒔 are the target and source coordinates. Since 𝑇𝐼𝐴(𝒓) = 1.0 for all 𝒓, the
integral simplifies to Equation 4.3.
∞

𝑫(𝒓) = ∫ 𝑫𝑷𝑲(𝒔)𝒅𝒔
𝟎

4.3
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that is, 𝐷(𝒓) is uniform and equal to the sum of all voxels in 𝐷𝑃𝐾(𝒓) which by energy
conservation is the energy of the emitted electron (500 keV) divided by the voxel mass
(1.03 g/cm3 x 0.0976 cm x 0.0976 cm x 0.351cm = 3.44 mg) to estimate the analytical
dose, 2.33 x 10-8 Gy (8.0109 Joules/3.44×10-6 kg) One kiloelectronvolts is equivalent to
1.60x10-16 Joules and 1 mg equals 10-6 kg. As the dose distribution calculated by Monte
Carlo simulation (e.g., egs_mird used in this work) by necessity is normalized by the total
TIA in the phantom. From Equation 2.10 (discussed in §2.3.3.1), the DPK simulation
with egs_mird is (𝐷𝑃𝐾(𝑥, 𝑦, 𝑧)), because the total TIA is 1.0 (the unit is arbitrary, it can
𝑁
be Bq.s) or ∑𝑀
𝑘=1 ∑𝑖,𝑗=1 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) = 1.0, then we can rewrite Equation 2.12 as:

𝑴𝑪𝒏𝒐𝒓𝒎 (𝒙, 𝒚, 𝒛) = 𝑫(𝒙, 𝒚, 𝒛) = 𝑫𝑷𝑲(𝒙, 𝒚, 𝒛)

4.4

From Equation 4.4, in other words, for DPK simulation, the dose is per unit of TIA (i.e.,
Bq.s). For a patient, egs_mird MC gives the dose distribution normalized by the total TIA
while the DPK normalized to per unit TIA convolves with the TIA distribution gives the
absolute dose distribution. Therefore, to compare the two dose distribution, we can use
two alternative approaches: normalize (divide) the DPK convolution dose distribution by
the total TIA so that it is the same as the normalized egs_mird dose distribution or
multiply the normalized egs_mird dose distribution by the total TIA. We also have to
normalize the analytical calculated normalized dose in the phantom, which is: 2.33 x 108

Gy/12,368,943 Bq.s or 1.88 𝜇𝐺𝑦. 𝐺𝐵𝑞 −1 . 𝑠 −1.

A Monte Carlo simulation was also used to calculate the dose distribution in the same
phantom as the DPK simulation. All simulations, both DPK and dose distribution, were
performed using 109 histories. The dose profiles for the normalized dose distribution
calculated by convolution and MC simulation were compared.

4.2.4

Patient-Specific 3D Dose Convolution and Monte Carlo
Simulation

Figure 4.1 shows the workflow used to perform 3D dose convolution using patientspecific PET and CT data. The 3D dose convolution was performed by convolving the
3D

177

Lu DPK from MC simulation with the 3D time-integrated activity from PET. The
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MC simulation of the 177Lu DPK used a 65 x 65 x 65 cm3 uniform phantom with density
and elemental composition according to the ICRU 46 shown in Table 4.2 at a voxel
resolution of 0.0976 cm x 0.0976 cm x 0.351 cm to match that of the anatomical CT scan.
Required simulation parameters were set similarly to §3.2.1. The DPK simulation was
averaged over a total of 3.0 x 109 particle histories to minimize uncertainties.

Figure 4.1: 3D Fast Fourier Transform dose convolution workflow
The 3D dose convolution calculation was implemented using the 3D fast Fourier
transform (FFT) technique in MATLAB for six patients (N=6). The flowchart in Figure
4.1 illustrates how the 3D FFT technique is used for 3D dose convolution. The procedure
involves a 3D FFT of the TIA distribution, TIA(xi,yj,zk) and of the dose point kernel,
DPK(xi,yj,zk). The 3D arrays were multiplied together and inverse Fourier transformed of
their product was implemented to yield the 3D absorbed dose D(xi,yj,zk).
To benchmark the 3D dose convolution algorithm, MC simulations without variance
reduction (VR) and with tracklength dose scoring (as a VR technique) were performed on
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the same six patients to generate the 3D dose distributions for comparison with those
from the convolution algorithm. As shown in Figure 4.1, MC simulation was performed
with the egsphant file and time-integrated activity file of 177Lu source generated from the
PET/CT studies. Simulation parameters were set similar to §3.2.1 and the scheme in
Table 4.1 was used to assign media to different structures outlined from the patient CT.
Simulations were performed using 109 histories.
The DPK convolution absorbed dose maps were corrected for density inhomogeneity
using a heuristic density correction method by scaling the DPK convolution maps voxel
by voxel by 1.04 g/cm3 (the density of the DPK phantom, Table 4.2) divided by CT scanbased voxel density. Density corrected DPK convolution maps were labeled as ‘DPK’
and those without density correction as ‘DPK without Den. Corr.’ MC simulation dose
maps were already density corrected in their generation. The time taken to perform DPK
convolution and egs_mird Monte Carlo simulation for patient-specific TRT dose
calculation was recorded and compared. All dose calculations were implemented using
AMD Ryzen 9 3900XT processor.

4.3 Results
4.3.1
4.3.1.1

Absorbed Dose Comparison between Analytical Calculation,
DPK Convolution and Monte Carlo Simulation
Results for No Radiation Transport

Shown in Figure 4.2 are profiles along the x-, y-, and z-axis of the DPK of a radionuclide
source that emits only 500 keV monoenergetic calculated by egs_mird when no radiation
transport. The DPK profile is a delta function with an absorbed dose of 2.3261 × 10−8
Gy at center voxel, the same as given by analytical calculation discussed in §4.2.3.
The absorbed dose distributions from a uniformly distributed radionuclide source
emitting a 500 keV monoenergetic electron at voxel TIA of 1 Bq.s were calculated using
DPK convolution and egs_mird noVR MC with no radiation transport. Figure 4.3
compares the x-dose profiles of the two dose distributions.

65

Figure 4.2: Dose point kernel (DK) of a radionuclide source emitting a 500 keV
monoenergetic electron plotted along the x-(green), y-(blue) and z-axis (pink) for no
radiation transport. The profiles along the x- and the y-axis overlap completely.

Figure 4.3: Dose profiles of the absorbed dose distributions in a phantom containing a
500 keV monoenergetic electron source at a uniform voxel TIA of 1 Bq.s calculated by
DPK convolution and noVR MC with no radiation transport.

66

The x-dose profile of the DPK convolution result was a uniform horizontal line at 1.8806
µGy·GBq−1·s−1 in good agreement with the analytical calculation of §4.2.3. While that of
the noVR MC showed a mean dose that is within 0.2% of the DPK convolution profile.

4.3.1.2

Results for Radiation Transport

The x-, y-, and z-axis profiles of the DPK of a radionuclide source emitting 500 keV
monoenergetic electrons with radiation transport are shown in Figure 4.4. The x- and yprofiles completely overlap each other. Figure 4.5 shows the absorbed dose comparison
between DPK convolution and egs_mird noVR MC with radiation transport for a 500
keV monoenergetic electron source distributed uniformly at a voxel TIA of 1 Bq.s in a

Figure 4.4: DPK with radiation transport of a 500 keV monoenergetic electron source
plotted along the x-(green), y-(blue) and z-axis (pink).
phantom. DPK convolution dose was uniform at 1.8797 µGy·GBq−1·s−1 in agreement
with analytical calculation (§4.2.3) throughout the phantom. The dose difference between
DPK convolution and egs_mird noVR MC was about 0.4 %.
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Figure 4.5: Dose profiles of the absorbed dose distributions in a phantom containing a
500 keV monoenergetic electron source at a uniform voxel TIA of 1 Bq.s calculated by
DPK convolution and noVR MC with radiation transport.

4.3.2

Patient-Specific 3D Dose Convolution and Monte Carlo
Simulation

Dose calculations were performed on six patients. Five patients received the
[18F]DCFPyL radiotracer; three have calcification in their prostate, while the other two
are free of calcification. In the remaining patient (N=1), there is calcification in the
prostate and the patient received [18F]FCH radiotracer. The absorbed dose percentage
difference between DPK convolution and full Monte Carlo simulation for all groups of
patients was consistent.
Based on time comparisons, TRT dose calculation in AMD Ryzen 9 3900XT processor
took 16.23 minutes with a single core for DPK convolution and 28.47 minutes for
egs_mird noVR Monte Carlo simulation on 22 cores.
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4.3.2.1

Voxelwise Dose Maps and Dose Profiles for a Patient with
Calcification in the Prostate that Received [18F]DCFPyL

Figure 4.6 illustrates a cross-section slice from the [18F]DCFPyL PET and CT study of a
patient with calcifications in the prostate showing various media assignments, density
distribution (map), and TIA maps for full and no activity in the calcifications of a patient
(IGPC-02-036). Magnified images of the prostate region are displayed for each TIA map.
Figure 4.7 are the density corrected radiation dose maps from simulated

177

Lu TRT

corresponding to the cross-sectional slice shown in Figure 4.6.

Figure 4.6: A cross-sectional slice from the [18F]DCFPyL PET/CT study of a patient
(IGPC-02-036) showing (a) media assignment, (b) density map, and TIA map for (c) full
activity and (d) noCalc denoting no activity in calcifications.
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Figure 4.7: Dose map from simulated

177

Lu TRT of the same cross-sectional slice as

Figure 4.7. in U = µGy·GBq−1·s−1 units. The dose maps were computed using DPK
convolution (top) and noVR egs_mird simulation (middle), an egs_mird simulation with
tracklength scoring (bottom). The left and right images show dose maps with (full) and
without (noCalc) activity in the calcifications, respectively. A magnified image of the
prostate is shown for each dose map.
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Figure 4.8: X- and Y-dose profile of the density corrected DPK convolution (red) and
noVR MC (blue) dose maps calculated using full activity TIA in calcifications of Figure
4.8 are shown here. The DPK simulation-derived uncertainties were convolved with the
time-integrated activity to generate error bars on the DPK plot while noVR uncertainties
were derived from MC simulation. The black arrows point to calcified regions.
The representative X- and Y-dose profiles of the density corrected DPK convolution
against noVR MC simulation maps with full activity in calcifications are shown in Figure
4.8. Both profiles cut across calcified voxels/regions in the prostate. The density
corrected DPK convolution dose profiles followed the same trend as those from the
noVR MC simulation. The density corrected DPK convolution dose uncertainties were
derived from convolving kernel uncertainties generated using egs_mird with the timeintegrated activity. The noVR MC dose uncertainties were generated by egs_mird.
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Figure 4.9: (A) X-dose profile of the density corrected DPK convolution (red) and noVR
MC (blue) dose maps with no activity in calcifications. (B) Y-dose profile of the same
dose maps as (A). (C) X-dose profiles of density corrected DPK convolution maps with
full (blue) and no (red) activity in the calcifications. (D) Y-dose profiles of the same dose
maps as in (C). The black arrows point to calcifications with no assumed activity in them.
Figure 4.9 shows the X- and Y-dose profiles of the density corrected DPK convolution
map against the noVR MC simulation map with no activity in the calcifications as well as
the dose profile comparison between density corrected DPK convolution maps with full
and no activity in calcifications. As expected, the density corrected DPK convolution
map showed the same trend as the noVR MC map with a dip in calcifications for no
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activity. The size of the calcifications was within the 0.0976 x 0.0976 pixels defined by
the CT, thus density corrected DPK convolution and noVR MC simulation dose maps
showed good spatial dose resolution by detecting the calcifications with either full or no
activity.

4.3.2.1.1

Analysis of Density Impact on DPK Convolution

To assess the impact of density heterogeneity on absorbed dose results, the DPK
convolution dose maps were also generated without density correction and the X- and Ydose profiles for maps with and without density correction are compared in Figure 4.10.

Figure 4.10: Comparison of (A) X- and (B) Y-dose profiles in DPK convolution dose
maps with (blue) and without (red) density correction. The maps were generated with full
activity in the calcifications. The black arrows point to the calcified region.
As the DPK was simulated in a phantom of the prostate density of 1.04 g/cm3 (see
§4.2.3), it is expected that for density higher than prostate, DPK convolution without
density correction overestimates the deposited dose while for lower density, the dose is
underestimated. As shown in Figure 4.10, the deposited dose obtained with density
corrected DPK showed dips in high-density regions like the calcification in the prostate
and bone regions while DPK without density correction smoothed out the dose profile.
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Thus, heterogeneity in density has an impact on dose results and care should be taken to
account for variations in media density in targeted radionuclide therapy.

4.3.2.1.2

Dose Volume Histogram for Patient with Calcifications
in the Prostate

Figure 4.11 shows DVHs for all calculation methods in prostate, rectum, bladder, and
bone marrow for the same patient as Figure 4.6 to Figure 4.10. In all tissue types, DPK
(full) and DPK (noCalc) convolution DVH results superimposed on each other
‘completely’ and the same is true for all DVHs from the egs_mird MC simulation with
either noVR or TL method.
To quantify the agreement between the dose distribution calculated by the density
corrected DPK convolution method and the standard of reference egs_mird MC
simulation method, the areas of the dose-volume histograms for the four regions: the
prostate, rectum, bladder, and bone marrow were compared.

Figure 4.11: Dose-volume histograms derived from dose distribution calculated with
density corrected DPK convolution calculations, noVR MC and TL MC using TIA
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matrices with full and no activity in calcifications for (A) prostate, (B) bladder, (C)
rectum, and (D) bone marrow.
The mean relative errors of DVHs for prostate, rectum, bladder, and bone marrow were 5.28 ± 0.82%, -5.21 ± 1.13%, -5.73 ± 0.73% and -15.60 ± 7.19%, respectively.
While for DPK without Den. Corr. the difference in DVH area against noVR MC is 6.44 ± 1.23%, -6.1 ± 1.39%, -8.69 ± 1.12%, and 6.10 ± 10.22% for prostate, rectum,
bladder, and bone marrow respectively.
Table 4.3: Average area under the DVH curve for the prostate and other organs at risk
like the rectum, and bone marrow for the different dose calculation methods.
Organ
Prostate
Rectum
Bone marrow

DPK without Den. Corr.
(µGy·GBq−1·s −1)
3.92
2.32
1.56

DPK
(µGy·GBq−1·s −1)
4.02
2.44
1.24

noVR
(µGy·GBq−1·s −1)
4.53
2.75
1.46

Dose (GyGBq-1s-1)

8
DPK without Den. Corr.
DPK
noVR

6

4

2

0
Prostate

Rectum

Bone marrow

Figure 4.12: Organ-level absorbed doses estimated using DPK convolution with and
without density correction compared to noVR MC.
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The total TIA over the patient body was 979.492 GBq⋅s. Table 4.3 is the mean absorbed
dose under the DVH curve for the prostate, rectum, and bone marrow also plotted in
Figure 4.12.

4.3.2.2

Voxelwise Dose Maps and Dose Profiles for a Patient
without Calcification in the Prostate that Received
[18F]DCFPyL

A cross-sectional slice from the [18F]DCFPyL PET/CT scan study showing various media
assignments, density map, and TIA maps are depicted in Figure 4.13.

Figure 4.13: A cross-sectional slice from the [18F]-DCFPyL PET/CT study of a patient
without calcifications in the prostate showing (a) media assignment, (b) density map, and
(c) TIA map.

Figure 4.14: Dose maps of a patient without calcification in the prostate from simulated
177

Lu TRT. The maps were computed using DPK convolution (left) and noVR egs_mird

simulation (middle), an egs_mird simulation with tracklength scoring (right). A
magnified image of the prostate is shown for each dose map. Dose values are expressed
in units of U = µGy·GBq−1·s−1.
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Figure 4.15: (A) The dose map of a cross-sectional slice superimposed on its
corresponding CT image with distance scales shown for the x- and y-axis. The x-dose
profiles of the

177

Lu DPK convolution (red) and noVR MC (blue) are shown in (B) and

the y-dose profiles in (C). The error bars on the dose profiles were obtained with the
uncertainties in the dose maps. These uncertainties were calculated as described in the
text.
This patient (IGPC-02-026) does not have calcified regions in the prostate. Figure 4.14
are the dose maps of a cross-sectional slice of the patient from the simulated 177Lu TRT.
Each dose map was normalized by the total TIA in the patient and is displayed in units of
µGy·GBq−1·s−1. The dose maps were calculated by DPK convolution and egs_mird (MC)
simulation with noVR and with tracklength scoring, TL. The representative dose profiles
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of the DPK convolution against noVR MC simulations are shown in Figure 4.15. The
dose profiles are plotted along the x-axis and the y-axis cutting across the hot nodule in
the prostate. The DPK convolution dose profile follows the same trend as the noVR MC
simulation. The DPK convolution absorbed dose uncertainties are derived from
convolving DPK kernel uncertainties generated using egs_mird with the time-integrated
activity. The noVR MC absorbed dose uncertainties are derived from MC dose scoring
uncertainties.

4.3.2.2.1

Analysis of Density Impact on DPK Convolution

The tissue density within the prostate and other regions was not uniform. Thus, to assess
the impact of density heterogeneity on dose results, dose profiles of DPK convolution
maps with and without density correction are compared in Figure 4.16.

Figure 4.16: The difference in dose profiles between DPK convolution maps calculated
using density correction (blue) and without density correction (red) using the activity TIA
map from [18F]DCFPyL. The dose is in units of µGy·GBq−1·s −1.
When the density of the medium is lower than that of the prostate used in the generation
of the DPK, the deposited dose is underestimated, while for media with a higher density,
the deposited dose is overestimated. Density corrected DPK convolution dose profile
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showed dips in high-density regions, while that without density correction smoothed over
density changes.

4.3.2.2.2

Dose Volume Histogram for Patient without
Calcifications in the Prostate

The DVHs from dose distributions of all calculation methods in prostate, rectum, bladder,
and bone marrow tissue are shown in Figure 4.17 shows. The mean absolute relative
errors of estimated absorbed doses between DPK convolution against MC simulations for
prostate, rectum, bladder, and bone marrow were -5.23 ± 0.81%, -5.12 ± 1.12%, 5.62 ± 0.49% and -17.12 ± 8.71%, respectively.

Figure 4.17: Dose volume histograms from dose distributions calculated by DPK
convolution and MC with noVR and with TL dose scoring. There were differences
between the DPK convolution and MC DVHs but the MC DVHs were the same.
For DPK convolution without density correction, the mean dose (or area of the DVH)
was consistently underestimated relative to noVR MC by -6.59 ± 1.01%, -6.13 ± 1.39%, -9.2 ± 0.78%, and -6.42 ± 2.90% for prostate, rectum, bladder, and bone marrow
respectively.
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Table 4.4: Total dose under the DVH curve for the prostate and other organs at risk like
the rectum, and bone marrow.
Organ
Prostate

DPK without Den. Corr.
(µGy·GBq−1·s −1)
5.68

DPK
(µGy·GBq−1·s −1)
5.71

noVR
(µGy·GBq−1·s −1)
6.50

Rectum

3.37

3.79

4.01

Bone marrow

1.58

1.27

1.51

Dose (GyGBq-1s-1)

8
DPK without Den. Corr.
DPK
noVR

6

4

2

0
Prostate

Rectum

Bone marrow

Figure 4.18: Organ-level absorbed doses estimated using DPK convolution with and
without density correction compared to noVR MC.
The total TIA over the patient body was 1215.797 GBq⋅s. The area average underneath
the DVH curves is the mean absorbed doses to prostate, rectum, and bone marrow
respectively shown in Table 4.4 and Figure 4.18.
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4.3.2.3

Voxelwise Dose Maps and Dose Profiles for a Patient with
Calcification in the Prostate that Received [18F]FCH

A cross-section slice from the [18F]FCH PET and CT study of a patient with
calcifications in the prostate showing various media assignments, density distribution
(map), and TIA maps for full and no activity in the calcifications of a patient (IGPC-02028) is shown in Figure 4.19. Magnified images of the prostate region are depicted for
each TIA map. Figure 4.20 are the density corrected radiation dose maps from simulated
177

Lu TRT corresponding to the cross-sectional slice shown in Figure 4.19. Each dose

map was normalized by the total TIA in the patient and is displayed in units of
µGy·GBq−1·s−1. The dose maps were calculated by DPK convolution and egs_mird (MC)
simulation with noVR and with tracklength scoring, TL.

Figure 4.19: A cross-sectional slice from the [18F]FCH PET and CT study of a patient
(IGPC-02-028) showing (a) media assignment, (b) density map, and TIA map for (c) full
activity and (d) noCalc denoting no activity in calcifications.
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Figure 4.20: Dose map from simulated

177

Lu TRT of the same cross-sectional slice as

Figure 4.19 in U = µGy·GBq−1·s−1 units. The dose maps were computed using DPK
convolution (top) and noVR egs_mird simulation (middle), an egs_mird simulation with
tracklength scoring (bottom). The left and right images show dose maps with (full) and
without (noCalc) activity in the calcifications, respectively. A magnified image of the
prostate is shown for each dose map.
The representative X- and Y-dose profiles of the density corrected DPK convolution
against noVR MC simulation maps with full activity in calcifications are shown in Figure
4.21. Both profiles cut across calcified voxels/regions in the prostate. The density
corrected DPK convolution dose profiles followed the same trend as those from the
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noVR MC simulation. The density corrected DPK convolution dose uncertainties were
derived from convolving kernel uncertainties generated using egs_mird with the timeintegrated activity. The noVR MC dose uncertainties were generated by egs_mird.

Figure 4.21: X- and Y-dose profile of the density corrected DPK convolution (red) and
noVR MC (blue) dose maps with full activity in calcifications of Figure 4.19 are shown
here. The DPK simulation-derived uncertainties were convolved with the time-integrated
activity to generate error bars on the DPK plot while noVR uncertainties were derived
from MC simulation.
Figure 4.22 shows the X- and Y-dose profiles of the density corrected DPK convolution
map against the noVR MC simulation map with no activity in the calcifications as well as
the dose profile comparison between density corrected DPK convolution maps with full
and no activity in calcifications. As expected, the density corrected DPK convolution
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map showed the same trend as the noVR MC map with a dip in calcifications with no
activity.

Figure 4.22: (A) X-dose profile of the density corrected DPK convolution (red) and
noVR MC (blue) dose maps with no activity in calcifications. (B) Y-dose profile of the
same dose maps as (A). (C) X-dose profiles of density corrected DPK convolution maps
with full (blue) and no (red) activity in the calcifications. (D) Y-dose profiles of the same
dose maps as in (C). The black arrows point to calcifications with no assumed activity in
them.
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4.3.2.3.1

Analysis of density impact on DPK convolution

To assess the impact of density heterogeneity on absorbed dose results, the DPK
convolution dose maps were also generated without density correction and the X- and Ydose profiles for maps with and without density correction are compared in Figure 4.23.

Figure 4.23: Comparison of (A) X- and (B) Y-dose profiles in DPK convolution dose
maps with (blue) and without (red) density correction. The maps were generated with full
activity in the calcifications. The black arrows point to calcification.
As the DPK was simulated in a phantom of the prostate density of 1.04 g/cm3 (see
§4.2.3), it is expected that for density higher than prostate, DPK convolution without
density correction overestimates the deposited dose while for lower density, the dose is
underestimated. As shown in Figure 4.23, the deposited dose obtained with density
corrected DPK showed dips in high-density regions like the calcification in the prostate
and bone regions while DPK without density correction smoothed out the dose profile.

4.3.2.3.2

Dose Volume Histogram

Figure 4.24 shows DVHs for all calculation methods in prostate, rectum, bladder, and
bone marrow for the same patient as Figure 4.19 to Figure 4.23. In all tissue types, DPK
(full) and DPK (noCalc) convolution DVH results superimposed on each other
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‘completely’ and the same is true for all DVHs from the egs_mird MC simulation with
either noVR or TL method.

Figure 4.24: Dose-volume histograms derived from dose distribution calculated with
density corrected DPK convolution calculations, noVR MC and TL MC using TIA
matrices with full and no activity in calcifications for (A) prostate, (B) bladder, (C)
rectum, and (D) bone marrow.
Table 4.5: Area under the DVH curve for the prostate and other organs at risk like the
rectum, and bone marrow for the different dose calculation methods.
Organ
Prostate
Rectum
Bone marrow

DPK without Den. Corr.
(µGy·GBq−1·s −1)
4.39
4.32
1.75

DPK
(µGy·GBq−1·s −1)
4.54
4.86
1.41

noVR
(µGy·GBq−1·s −1)
5.20
5.46
1.68

To evaluate the agreement between the dose distribution calculated by the density
corrected DPK convolution method and the standard of reference egs_mird MC
simulation method, the areas of the dose-volume histograms for the four regions: the
prostate, rectum, bladder, and bone marrow were compared. The mean relative errors of
DVHs for prostate, rectum, bladder, and bone marrow were -5.55 ± 0.79%, 5.36 ± 1.32%, -5.83 ± 0.50% and -14.68 ± 6.25%, respectively. While for DPK
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convolution without density the dose variation against noVR MC is -6.86± 0.95%, 6.86 ± 1.28%, -10.01 ± 0.85%, and 6.48 ± 2.85% for prostate, rectum, bladder, and bone
marrow respectively.

Dose (GyGBq-1s-1)

8
DPK without Den. Corr.
DPK
noVR

6

4

2

0
Prostate

Rectum

Bone marrow

Figure 4.25: Organ-level absorbed doses estimated using DPK convolution with and
without density correction compared to noVR MC.
The total TIA over the patient body was 1270.243 GBq⋅s. Table 4.5 is the mean absorbed
dose under the DVH curve for the prostate, rectum, and bone marrow plotted in Figure
4.25.

4.4 Discussion
As currently practiced, patients in targeted radionuclide therapy are administered a fixed
radionuclide activity regardless of their body weight and personalized radiation dose
calculation from the administered activity is not performed. As a result, the tumor and
critical organs could either be over- or under-dose leading to suboptimal treatment
efficacy and/or increased rates of complications. Voxelized absorbed dose calculation is
preferable to organ-level mean absorbed doses calculated with the MIRD formalism as
hot and cold spots could be overlooked with the latter method. The Monte Carlo (MC)
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simulation method is considered the gold standard for calculating voxelized absorbed
doses in targeted radionuclide therapy. However, MC simulation is complex and
computationally demanding if it is required for each patient.
In this work, a 3D FFT convolution method for voxel-level dose calculation method was
developed for application in targeted radionuclide therapy and diagnostic nuclear
medicine procedures. This method has been demonstrated in simulated

177

Lu targeted

radionuclide therapy for (N=6) six patients using the [18F]DCFPyL or [18F]FCH PET/CT
data of each patient. Five patients were administered [18F]DCFPyL and only one received
[18F]FCH.
The MC simulation used egs_mird, a EGSnrc MC application developed by Dr. M
Martinov of our group.233 The 177Lu 3D dose point kernel in homogeneous prostate media
at 1.04 g/cm3 density was generated with egs_mird. The size of the kernel was 65 cm and
photon energy loss in the kernel was roughly 1%. The patient absorbed dose was
calculated by convolving the 177Lu dose point kernel dose with patient-specific timeintegrated activity. The convolution calculated absorbed dose for each voxel was further
scaled with the prostate density of 1.04 g/cm3 divided by the real density values derived
from the CT scan to correct for the density deviation of each voxel from the assumed
prostate density. The density corrected DPK convolution absorbed dose results were
compared with those of egs_mird MC.
The DPK convolution method can perform a TRT treatment simulation using a precalculated

177

Lu DPK and patient-specific time-integrated activity data in 16.23 minutes

with a single core of AMD Ryzen 9 3900XT processor. On the contrary, the egs_mird
noVR Monte Carlo simulation took 28.47 minutes using 22 cores of the same Ryzen 9
3900XT processor.
Figure 4.6, Figure 4.13 and Figure 4.19 illustrate patients’ CT, [18F]DCFPyL, and
[18F]FCH PET data side by side. Due to the reduced spatial resolution, the calcifications
are not as visible in the PET scans as they are on the CT scans for patients with calcified
prostate regions. The 3D TIA map was derived from the dynamic PET data and
represented a TIA across a 22-minute scan in each voxel.
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Although the noise level in DPK convolution dose maps appeared to be the same as the
egs_mird MC dose maps shown in Figure 4.7, Figure 4.14 and Figure 4.20, the dose
profiles from the DPK convolution dose map were less noisy than the egs_mird MC dose
map as shown in Figure 4.8 to Figure 4.9, Figure 4.15 and Figure 4.21 to Figure 4.22.
The fluctuations in the dose profiles reflect the statistical uncertainties of the DPK
convolution and MC dose calculations. While both noise in the TIA map and the MC
simulation process contributed to the noise in egs_mird dose maps, only that in the TIA
map contributed to the noise in the DPK convolution dose map.
In this study, calcifications were modelled as an equal mix by mass of prostate tissue and
pure calcification. Further, by assuming full and no activity in the calcifications, then the
TIA in these calcified regions was halved and the corresponding dose declined by 40%.
For all patients, the presence of calcifications in the prostate did not noticeably affect the
immediately surrounding voxels, namely spurious increase or decrease of dose were not
observed. It is worth noting that the pure calcification voxels still have dose deposition
even when the TIA in them is set to zero, indicating that there is at least some dose
contribution from adjacent non-calcification voxels. This is a strong indication that the
reduced energy deposited in the P50C50 voxels would not be entirely localized within the
prostate fraction of the voxel media if the different media in the voxel were to be
modelled explicitly.
DPK convolution consistently demonstrated a lower dose compared to MC. This
discrepancy between the models could stem from several factors. One factor is the PET
scan noise which is the only substantial noise source that the DPK convolution must deal
with, although the PET scan activity was up-sampled using linear interpolation from
128x128 to 512x512 resolution, improving the smoothness between neighboring voxels.
Furthermore, the convolution kernel assumes that all voxels are prostate tissue with a
density of 1.04 g/cm3 and does not account for density variation. The tissue density
inhomogeneities in the patient's body could contribute to systemic discrepancies between
DPK convolution and MC calculated doses. Figure 4.10, Figure 4.16 and Figure 4.23
show the effect of a simple density correction performed on DPK convolution at the
voxel level on accounting for density inhomogeneity. As a result of this correction, the
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accuracy of the DPK convolution dose was improved relative to MC simulation,
particularly for high-density objects, that is those whose density differs significantly from
that used in the DPK simulation. Another factor is the variation in the mass energy
absorption coefficient. For

177

Lu, about 22% are photon decays, for these decays, the

change in mass energy absorption coefficients with energy and media composition can
further contribute to the discrepancy between DPK convolution and MC.
To verify that the DPK convolution and MC dose calculations agree when removing all
the above discrepancies, simulations were performed using a radionuclide source that
emits only 500 keV electrons. The simulation was performed with a cuboid phantom (65
cm)3 in size that was uniformly filled with prostate media at a density of 1.03 g/cm3. The
time-integrated activity per phantom voxel was also 1 Bq.s. The dose distribution in the
phantom calculated with MC simulation was compared to that calculated with DPK
convolution using prostate media and prostate density DPK. The two dose distributions
agreed to within 0.2 %. Furthermore, there was no difference in dose calculated with
DPK convolution and analytically. This comparison shows that when discrepancies in
density inhomogeneity and other factors, e.g., mass energy absorption coefficient
discussed above, are removed, the dose calculated by DPK convolution and MC
simulation is the same. It also shows that DPK convolution dose calculation can be
inaccurate in tissue/media with prominent density inhomogeneity, e.g., the lungs.

4.5 Conclusion
The present study demonstrates that DPK convolution can be used to calculate a patientspecific absorbed dose distribution in TRT using patient CT for the definition of patient
geometry and density distribution and PET scans for integrated time activity distribution.
Due to the difference in tissue media and densities, the DPK convolution dose for

177

Lu

TRT was approximately 5.6 % lower on average than the egs_mird MC simulation dose
for the prostate and rectum. As such, the DPK convolution method may not be suitable
for TRT dose calculation for tumors within tissue regions of high-level inhomogeneities
like bone or lung tissue regions. Further work is required to adapt DPK convolution to
account for tissue media and density inhomogeneities.
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Chapter 5

5

Conclusion and Future Directions

5.1 Summary
In many well-established MC codes, dose calculations are typically based on assumptions
about patient geometry and activity distribution. We developed egs_mird for patientspecific targeted radionuclide therapy dosimetry, to overcome the challenges associated
with other Monte Carlo codes The purpose of this master's thesis is two-fold. Firstly, to
validate egs_mird (an in-house Monte Carlo (MC) simulation code) and see if it agrees
with well-established MC codes. Secondly, to develop a 3D voxel-level dose convolution
algorithm and investigate whether it is fast and accurate for patient-specific TRT
dosimetry in prostate cancer. egs_mird MC code was developed to calculate patientspecific absorbed dose distribution in TRT using patient CT for the definition of patient
geometry and density distribution and PET scans for integrated time activity distribution.
I participated and contributed to the development of the egs_mird MC dosimetry program
for internally distributed radionuclides by generating DPKs for 90Y, 131I and 177Lu with
the program and critically comparing the results with the literature. The DPKs showed
good agreement, and the discrepancy between our

177

Lu DPK and literature was due to

differences in emission spectra. It illustrates the importance of using the correct emission
spectrum when calculating DPKs.
I developed a 3D dose convolution algorithm to calculate 3D dose distributions of
radionuclides using the dose point kernel (DPK) and the time-integrated activity (TIA) of
the radionuclide. The 3D convolution algorithm 3D dose results were validated using
analytical calculations and egs_mird MC simulation. The 3D dose distribution was in
good agreement with analytical calculations (0%) and egs_mird MC simulations (0.2%0.4%).
I used the 3D dose convolution algorithm and egs_mird MC simulation to calculate 177Lu
TRT dose distributions in 3D for six patients. The DVHs were similar, but the mean
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doses in the prostate and critical organs were 5-7% lower with DKP convolution than in
the MC simulation. The reason is the density inhomogeneity. Moreover, an ad-hoc
method for density correction brings the results closer to MC simulation in the calcified
regions of the prostate, rectum and bladder than without the ad-hoc correction method.
The comparison was worse for bone marrow.

5.2 DPK Convolution Density Correction
The TRT clinical practice relies on accurate TRT treatment planning systems based on
absorbed dose distributions. The absorbed dose is affected by tissue heterogeneities and
finite patient geometry.247 DPK convolution depends on the dose point kernel, mostly in a
homogeneous medium which limits absorbed dose accuracy. A more accurate dose
convolution technique considers how ionizing radiation interacts with the body of the
patient in the 3D spatial distribution of tissue heterogeneities.
Energy is deposited along the primary and secondary electron tracks as ionizing
radiations (radionuclides used in TRT emit ionizing radiation such as photons, beta
particles, electrons, alpha particles, etc.) interact with the body of the patient. These
ionizing radiations frequently experience scattering processes and can participate in
multiple scattering processes because of density variations before imparting all their
energy to the patient's body or escaping.212
Future work will account for tissue density inhomogeneities by recalculation of the dose
point kernel. Approximately, the kernel can be scaled by the prostate/water equivalent
distance along rays between the source and dose-receiving points.248 For most clinical
situations, this method will provide a fast and sufficiently accurate way to incorporate
inhomogeneities into 3D dose calculations, and it has been implemented in external beam
radiotherapy. Instead of physical distance, the in-prostate/water kernel values are
calculated along rays radiological distance using Equation 5.1.
̅(𝒔, 𝒓) = 𝝆′𝒆 (𝒓)(𝝆
̅𝒑 [𝝆′𝒆 (𝒓 − 𝒔)]
̅′𝒆 )𝟐 𝒌
𝒌

5.1

where 𝜌́ 𝑒 (𝒓) = 𝜌𝑒 (𝒓)/𝜌𝑒𝑝 (𝒓) is the local relative electron density at r, 𝜌̅𝑒′ is the average
relative electron density along the path from point s to r
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𝒓

̅ ′𝒆
𝝆

∫ 𝝆′𝒆 (𝒍) 𝒅𝒍
= 𝒔
|𝒓 − 𝒔|

5.2

and 𝑘̅𝑝 is the kernel for a prostate or water medium.
The energy deposited per unit volume in the prostate is multiplied by the local relative
electron density, 𝜌𝑒′ (𝒓) and the (𝜌̅𝑒′ )2 the factor is used to compensate for the integrated
inverse-square fall-off with physical distance in the values of the prostate or water
kernels.
The dose-receiving point experiences a different density environment but stays at the
𝑟

same physical location relative to the source. From Equation 5.2, the integral ∫𝑠 𝜌𝑒′ (𝑙) 𝑑𝑙
is the radiological distance, while the |𝒓 − 𝒔| is the geometric distance.
The 3D absorbed dose is now calculated by convolving the recalculated prostate or water
kernel, 𝑘̅(𝒔, 𝒓) (in Equation 5.1) with the time-integrated activity from each patient.

5.3 Estimation of Biological Effective Dose
The objective of dosimetry treatment-planning protocols in targeted radionuclide therapy
is to prescribe a clinically useful absorbed dose to the tumor while at the same time
avoiding

organ

toxicity.

However,

patients

with

rapid

clearance

of

the

radiopharmaceutical require a larger amount of initial activity than those with slow
clearance to match the absorbed dose to the target and critical organ.249 An increase in
absorbed dose, arising from a large, administered activity may cause an unexpected
increase in toxicity among the dose-limiting normal tissues, such as the red bone marrow
and kidneys due to the more rapid clearance of radiopharmaceuticals from the body of a
patient. Even though the total absorbed dose to a dose-limiting tissue remains constant,
the absorbed dose can vary substantially among patients.249
Targeted radionuclide therapy dose delivery induces DNA damage both in the cancer cell
and in normal tissues. DNA repair takes place faster in normal tissues than in cancer
cells. The repair process in the interval between irradiation competes with the induction
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of further DNA sublethal damage leading to a more lethal effect by the ongoing
irradiation.250 Thus, a more general model is required to account for the biological impact
of different absorbed doses. These effects may be accounted for through the biological
effective dose (BED). BED may be applied to evaluate how radiation delivery in TRT
might impact on overall balance between the probabilities of tumor cure and normaltissue complications.250–253 The BED is the dose required for a given biological effect
when delivered by infinitely small doses per fraction or at very low doses and is typically
used to compare the response implications of total absorbed doses delivered at different
doses. BED also relates absorbed dose with radiosensitivity and repair of radiation
damage using the standard linear quadratic model.254 In future work, BED modeling will
be implemented to account for the impact of targeted radionuclide therapy on the target
organ, prostate, dose-limiting organs, and other organs at risk.

5.4 Estimation of Time-Integrated Activity
Dosimetry for radionuclide therapy involves calculating the time-integrated activity.
Time-integrated activity for current work is estimated using a PET study acquired within
five-time points (~22 minutes). For calculating absorbed doses, future work will account
for time-integrated activity until radiopharmaceuticals are eliminated from the body.
In most cases, blood samplings are taken to determine the level of activity in the blood.255
(including various organs) and to estimate the biological half-life of radiopharmaceuticals
in the body. Using Equation 5.3, we can estimate the time-integrated activity of
radiopharmaceuticals administered to a patient from the time of administration to the time
of elimination.

∞

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) = ∫ 𝑨(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝒅𝒕

5.3

𝟎

The time-integrated activity 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) can be calculated using exponential
extrapolation and kinetic modelling.
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5.4.1

Exponential Extrapolation

The exponential extrapolation of 𝑇𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡) is based on the fitting from the peak
(𝑡 = 𝑡𝑝 ) to 𝑡 = 𝑡𝑒 where 𝑡𝑒 is the end of the measurement. Let the extrapolated curve be
𝑇𝐴𝑒 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡), then:
𝑡𝑒

∞

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) = ∫ 𝑇𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝑑𝑡 + ∫ 𝑇𝐴𝑒 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝑑𝑡
0

𝑡𝑒

5.4

where ∞ is the shorter of five biological or physical half-lives of the radionuclide at
voxel (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ).

5.4.2

From Kinetic Modelling
∞

∞

∞

𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) = ∫ 𝑇𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝑑𝑡 = [∫ 𝐶𝑎 (𝑡)𝑑𝑡] ∙ [∫ 𝑅𝐹 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝑑𝑡]
0

0

0

5.5

where 𝐶𝑎 (𝑡) is the arterial curve and 𝑅𝐹 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡) is the flow–scaled impulse residue
function, that is,
𝑇𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡) = 𝐶𝑎 (𝑡) ⊗ 𝑅𝐹 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)
where ⊗ is the convolution operator. It can be shown that:
∞

∫ 𝑅𝐹 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 , 𝑡)𝑑𝑡 = 𝑉𝑏 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) + 𝑉𝐷 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) = 𝑉𝑇 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 )

5.6

0

where 𝑉𝑏 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) is the blood volume, 𝑉𝐷 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) is the Logan distribution volume,
∞

and 𝑉𝑇 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) is the total distribution volume. Since ∫0 𝐶𝑎 (𝑡)𝑑𝑡 = 𝐾𝑐 is a constant,
Equation 5.5 shows that 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) is proportional to 𝑉𝑇 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ). Therefore, as
shown in Equation 2.9 in §2.3.31, 𝑃(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) can also be determined with 𝑉𝑇 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ),
or egs_mird can use 𝑉𝑇 (𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) instead of 𝑇𝐼𝐴(𝑥𝑖 , 𝑦𝑗 , 𝑧𝑘 ) to calculate the normalized
dose, 𝑀𝐶𝑛𝑜𝑟𝑚 (𝑥, 𝑦, 𝑧), or the dose per decay. As in Equation 5.4:
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∞

𝑡𝑒

∞

∫ 𝐶𝑎 (𝑡)𝑑𝑡 = ∫ 𝐶𝑎 ( 𝑡)𝑑𝑡 + ∫ 𝐶𝑎𝑒 ( 𝑡)𝑑𝑡
0

0

5.7

𝑡𝑒

where 𝑡𝑒 is the end of the measurement of 𝐶𝑎 (𝑡) and 𝐶𝑎𝑒 ( 𝑡) is the exponential
extrapolation of 𝐶𝑎 ( 𝑡) based on the fitting from the peak (𝑡 = 𝑡𝑝 ) to 𝑡 = 𝑡𝑒 .
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Appendix B: Dose Point Kernel Input File
#------------------------------------------------------------------------------:start run control:
ncase = 3e9
nbatch = 1
calculation = First
:stop run control:
#------------------------------------------------------------------------------:start media definition:
# All Transport
AE = 00.512
UE = 01.511
AP = 00.001
UP = 01.000
material data file = EGSnrc/egs_home/egs_mird/material.dat
:stop media definition:
#------------------------------------------------------------------------------####################################################################
#
Phantom definition
####################################################################
:start geometry definition:
: Start geometry:
library = egs_ndgeometry
type
= EGS_XYZGeometry
Name = Phantom
x-planes = -0.45 -0.35 -0.25 -0.15 -0.05 0.05 0.15 0.25 0.35 0.45 # Should be changed
y-planes = -0.45 -0.35 -0.25 -0.15 -0.05 0.05 0.15 0.25 0.35 0.45 # Should be changed
z-planes = -0.45 -0.35 -0.25 -0.15 -0.05 0.05 0.15 0.25 0.35 0.45 # Should be changed
:start media input:
media = Prostate
:stop media input:
:stop geometry:
simulation geometry = Phantom
:stop geometry definition:
#------------------------------------------------------------------------------####################################################################
#
source definition
####################################################################
:start source definition:
: Start Source:
library = egs_internal_source
Name = the_source_1
geometry = Phantom
charge = 0
regions = 364 #should be changed depending on the Phantom configuration
weights = 1
: Start spectrum:
type
= monoenergetic
energy = 1.0
:stop spectrum:
:stop source:
: Start Source:
Name = the_source
library = egs_radionuclide_source
base Source = the_source_1
: Start spectrum:
type
= radionuclide
nuclide = Lu - 177
:stop spectrum:
:stop source:
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simulation Source = the_source
:stop source definition:
#------------------------------------------------------------------------------########################################################################
#
Scoring options
########################################################################
:start scoring options:
type
= 3ddose
file name
= FileName.3ddose
scoring geometry = Phantom
:stop scoring options:
:start rng definition:
type
= ranmar
initial seeds
= 28 29
high resolution = yes
:stop rng definition:
:start MC transport parameter:
Global ECUT
Global PCUT
Global SMAX
Bound Compton Scattering
Rayleigh Scattering
Atomic Relaxations
Photoelectron Angular Sampling
Electron Impact Ionization
Brems Angular Sampling
Brems Cross Sections
Pair Angular Sampling
ESTEPE
XIMAX
Skin Depth for BCA
Boundary Crossing Algorithm
Electron-Step Algorithm
Spin Effects
Radiative Compton Corrections
Photon Cross Sections
Fluorescent Photon Cutoff
:stop MC transport parameter:

=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=

0.512
0.001
1e10
On
On
On
On
On
KM
nist
Off
0.25
0.5
3.0
EXACT
PRESTA-II
On
Off
xcom
0.001

Appendix C: egs_mird Input File for Patient simulation
#------------------------------------------------------------------------------:start run control:
ncase
= 1e9
nbatch
= 1
nchunk
= 1
:stop run control:
#------------------------------------------------------------------------------:start media definition:
AE
UE
AP
UP

=
=
=
=

00.512
01.511
00.001
01.000

material data file = /EGSnrc/egs_home/egs_mird/material.dat
:stop media definition:
#------------------------------------------------------------------------------:start geometry definition:
:start geometry:
library
= egs_glib
type
= egsphant
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name
= phantom
egsphant file = /EGSnrc/egs_home/egs_mird/FileName.egsphant
density file = /EGSnrc/egs_home/egs_mird/material.dat
:stop geometry:
simulation geometry = phantom
:stop geometry definition:
#------------------------------------------------------------------------------:start source definition:
:start source:
library
= egs_internal_source
name
= the_source_location
geometry
= phantom
activity file = /EGSnrc/egs_home/egs_mird/ActivityFileName.txt
charge
= 0 # Input is ignored
:start spectrum:
type
= monoenergetic # Input is ignored
energy = 1.0 # Input is ignored
:stop spectrum:
:stop source:
:start source:
name
= the_source
library
= egs_radionuclide_source
base source = the_source_location
:start spectrum:
type
= radionuclide
nuclide = Lu-177
:stop spectrum:
:stop source:
simulation source = the_source
:stop source definition:
#------------------------------------------------------------------------------:start scoring options:
type
= 3ddose
scoring geometry
= phantom
file name
= FileName.3ddose
:stop scoring options:
#------------------------------------------------------------------------------:start variance reduction:
score tracklength dose
= no
muen file
= /EGSnrc/egs_home/egs_mird/XCOM_muen_1500keV.muendat
:stop variance reduction:
#------------------------------------------------------------------------------:start rng definition:
type
= ranmar
initial seeds
= 28 29
high resolution = yes
:stop rng definition:
#------------------------------------------------------------------------------:start MC transport parameter:
Global ECUT
= 0.512
Global PCUT
= 0.001
Global SMAX
= 1e10
Bound Compton Scattering
= On
Rayleigh Scattering
= On
Atomic Relaxations
= On
Photoelectron Angular Sampling = On
Electron Impact Ionization
= On
Brems Angular Sampling
= KM
Brems Cross Sections
= nist
Pair Angular Sampling
= Off
ESTEPE
= 0.25
XIMAX
= 0.5
Skin Depth for BCA
= 3.0
Boundary Crossing Algorithm
= EXACT
Electron-Step Algorithm
= PRESTA-II
Spin Effects
= On
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Radiative Compton Corrections = Off
Photon Cross Sections
= xcom
Fluorescent Photon Cutoff
= 0.001
:stop MC transport parameter:
#-------------------------------------------------------------------------------
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